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A B S T R A C T
Background
People with asthmamay experience exacerbations or “attacks” during which their symptomsworsen and additional treatment is required.
Written action plans may advocate doubling the dose of inhaled steroids in the early stages of an asthma exacerbation to reduce the
severity of the attack and to prevent the need for oral steroids or hospital admission.
Objectives
To compare the clinical effectiveness and safety of increased versus stable doses of inhaled corticosteroids (ICS) as part of a patient-
initiated action plan for home management of exacerbations in children and adults with persistent asthma.
Search methods
We searched the Cochrane Airways Group Specialised Register, which is derived from searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cumulative Index to Nursing and AlliedHealth Literature (CINAHL)
to March 2016. We handsearched respiratory journals and meeting abstracts.
Selection criteria
We included randomised controlled trials (RCTs) that compared increased versus stable doses of ICS for home management of asthma
exacerbations. We included studies of children or adults with persistent asthma who were receiving daily maintenance ICS.
Data collection and analysis
Two review authors independently selected trials, assessed quality and extracted data. We contacted authors of RCTs for additional
information.
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Main results
This review update added three new studies including 419 participants to the review. In total, we identified eight RCTs, most of which
were at low risk of bias, involving 1669 participants with mild to moderate asthma. We included three paediatric (n = 422) and five
adult (n = 1247) studies; six were parallel-group trials and two had a cross-over design. All but one study followed participants for six
months to one year. Allowed maintenance doses of ICS varied in adult and paediatric studies, as did use of concomitant medications
and doses of ICS initiated during exacerbations. Investigators gave participants a study inhaler containing additional ICS or placebo
to be started as part of an action plan for treatment of exacerbations.
The odds of treatment failure, defined as the need for oral corticosteroids, were not significantly reduced among those randomised to
increased ICS compared with those taking their usual stable maintenance dose (odds ratio (OR) 0.89, 95% confidence interval (CI)
0.68 to 1.18; participants = 1520; studies = 7). When we analysed only people who actually took their study inhaler for an exacerbation,
we found much variation between study results but the evidence did not show a significant benefit of increasing ICS dose (OR 0.84,
95% CI 0.54 to 1.30; participants = 766; studies = 7). The odds of having an unscheduled physician visit (OR 0.96, 95% CI 0.66
to 1.41; participants = 931; studies = 3) or acute visit (Peto OR 0.98, 95% CI 0.24 to 3.98; participants = 450; studies = 3) were not
significantly reduced by an increased versus stable dose of ICS, and evidence was insufficient to permit assessment of impact on the
duration of exacerbation; our ability to draw conclusions from these outcomes was limited by the number of studies reporting these
events and by the number of events included in the analyses. The odds of serious events (OR 1.69, 95% CI 0.77 to 3.71; participants
= 394; studies = 2) and non-serious events, such as oral irritation, headaches and changes in appetite (OR 2.15, 95% CI 0.68 to 6.73;
participants = 142; studies = 2), were neither increased nor decreased significantly by increased versus stable doses of ICS during an
exacerbation. Too few studies are available to allow firm conclusions on the basis of subgroup analyses conducted to investigate the
impact of age, time to treatment initiation, doses used, smoking history and the fold increase of ICS on the magnitude of effect; yet,
effect size appears similar in children and adults.
Authors’ conclusions
Current evidence does not support increasing the dose of ICS as part of a self initiated action plan to treat exacerbations in adults and
children with mild to moderate asthma. Increased ICS dose is not associated with a statistically significant reduction in the odds of
requiring rescue oral corticosteroids for the exacerbation, or of having adverse events, compared with a stable ICS dose.Wide confidence
intervals for several outcomes mean we cannot rule out possible benefits of this approach.
P L A I N L A N G U A G E S U M M A R Y
Increasing the dose of inhaled steroids or continuing the usual dose to treat asthma attacks in adults and children
Background
Previous asthma treatment guidelines recommended doubling the dose of inhaled corticosteroids (ICS) at the first sign of an asthma
attack as part of an action plan. We looked for all studies that have assessed whether such an increase is better than and is as safe as
carrying on with the usual ICS dose.
Study characteristics
This review update added three new studies including 419 participants to the review. We performed the most recent searches in March
2016. In total, we found eight studies involving 1669 people with mild or moderate asthma. Three were conducted in children, and
five in adults. These studies provided participants with an inhaler that contained extra doses of ICS (to increase their usual ICS dose)
or a placebo that could be used if their symptoms worsened. Participants were then followed for six months to one year to see whether
people taking more inhaled corticosteroids during attacks did better than those who took a placebo.
Key results
People taking an increased dose of ICS during an attack did not do better than those who took a placebo, regardless of whether we
looked at all study participants or only those who actually took the inhalers during an attack. Results showed a lot of variation in studies
that focused only on people who took the inhalers, with some studies showing benefit of increasing ICS dose and others showing no
benefit. It is unlikely that increasing ICS dose reduces the need for a course of oral steroids to treat the attack, prevents the need for an
emergency visit with doctors or at the hospital or reduces the time it takes to recover. We cannot be sure of these last results because
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few studies reported them. Use of either strategy was not associated with significantly more or less serious and non-serious side effects,
but again we cannot say for sure because we did not find enough studies.
Quality of the evidence
We have rated results of this review as having moderate or low quality, depending on the outcome. This means that some of the findings
were very uncertain, mainly because the studies included very few people who could say definitively whether increasing the dose was
better or worse than, or no different from, keeping the dose stable.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Patient or population: adults and children with chronic asthma
Setting: outpat ient
Intervention: increased ICS dose during exacerbat ions
Comparison: stable ICS dose during exacerbat ions
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with stable ICS Risk with increased ICS
Treatment failure -
need for systemic cor-
ticosteroids (ITT)
45 weeks
179 per 1000 163 per 1000
(129 to 205)
OR 0.89
(0.68 to 1.18)
1520
(7 RCTs)
⊕⊕⊕©
MODERATEa,i,j
Favours increasing ICS
but not stat ist ically sig-
nif icant
Non-signif icant sub-
group dif ferences for
age, ICS dose (baseline
or increased) and ICS
fold increase
Treatment failure -
need for systemic cor-
ticosteroids (of those
starting inhaler)
45 weeks
337 per 1000 299 per 1000
(215 to 398)
OR 0.84 , (0.54 to 1.30) 766
(7 RCTs)
⊕⊕©©
LOWb,c,i,j
No clear benef it of one
strategy over the other.
Too imprecise to infer
no dif ference
Analysed using ran-
dom-ef fects models be-
cause of heterogeneity
Unscheduled physician
visits
44 weeks
147 per 1000 142 per 1000
(102 to 195)
OR 0.96
(0.66 to 1.41)
931
(3 RCTs)
⊕⊕©©
LOWd,e,i,j
For both of these out-
comes, no clear bene-
f it of one strategy over
the other was noted,
but the est imate was
too imprecise to con-
f irm no dif ferences be-
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tween them
Unscheduled
acute care, ED visit or
hospital admission
47 weeks
18 per 1000 18 per 1000
(4 to 67)
OR 0.98
(0.24 to 3.98)
450
(3 RCTs)
⊕⊕©©
LOWf,i,j
Duration of exacerba-
tion - time to symp-
tom recovery and lung
function recovery
52 weeks
Mean time to symptom
recovery was 6.1 days
Time to lung funct ion
recovery was 7 days
Time to symptom re-
covery was 0.7 days
longer in the interven-
t ion group (1.06 lower
to 2.46 higher)
Time to lung funct ion
recovery was 0.2 days
shorter (1.88 lower to
1.48 higher)
- 207
(1 RCT)
⊕⊕⊕©
MODERATEb,d,i,j
Serious adverse events
48 weeks
56 per 1000 91 per 1000
(44 to 181)
OR 1.69
(0.77 to 3.71)
394
(2 RCTs)
⊕⊕⊕©
MODERATEg,h,i,j
Favours stable dose but
conf idence intervals do
not rule out greater
safety with increased
dose
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI)
CI: conf idence interval; ED: emergency department; ICS: inhaled cort icosteroids; ITT: intent ion-to-treat populat ion; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aThe ef fect was in favour of increasing ICS, but the conf idence interval included no ef fect and the possibility of appreciable
benef it of keeping the dose stable (-1 imprecision)
bUpper and lower conf idence intervals include important benef it of both treatments (-1 imprecision)
cI2 = 55%, P value = 0.04; clear variat ion was noted between direct ion and magnitude of study results by visual inspect ion of
the forest plot (-1 inconsistency)5
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dSeveral studies did not appear in the analysis, but contact with study authors meant this was unlikely because of select ive
report ing (no downgrade for publicat ion bias)
eThree studies observed 136 events leading to very wide conf idence intervals, which made the result very dif f icult to interpret
(-2 imprecision)
f Only eight events in the analysis, leading to a large amount of imprecision in the est imate. Two studies did not observe any
events so did not contribute to the ef fect est imate (-2 imprecision)
gConf idence intervals included a signif icant increase in adverse events on increased dose ICS and did not exclude the
possibility of no dif ference against stable ICS. Very few events were included in either of the adverse event analyses (-1
imprecision)
hOnly two studies explicit ly reported serious adverse events separately f rom the other exacerbat ion and resource use
outcomes (no downgrade for publicat ion bias)
iWe noted some uncertaint ies regarding allocat ion concealment and missing data imputat ion, but only in some studies, and
this was not deemed signif icant enough to have had a serious impact on the results (no downgrade for risk of bias across
outcomes)
jAll studies were well matched to the quest ion posed by the review. We resolved uncertaint ies in the def init ions of outcomes
through contact with study authors, so we were conf ident the data were relevant to each outcome of interest (no downgrade
for indirectness across outcomes)
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B A C K G R O U N D
Description of the condition
Asthma is a common chronic breathing condition that is esti-
mated to affect as many as 334 million people (Global Asthma
Report 2014). Asthma exacerbations involve short-term worsen-
ing of symptoms, which vary from mild to life-threatening, and
are associated with significant morbidity, mortality and healthcare
expenditure (Sears 2000). Up to a quarter of patients presenting to
the emergency roomwith asthma exacerbations ultimately require
hospitalisation (Pollack 2002), resulting in a three-fold increase in
costs compared with costs of management in a primary care setting
(Lane 2006). Asthma exacerbations are very frightening for pa-
tients and can have a negative impact on health-related quality of
life (Lloyd 2007). Achieving early control of asthma exacerbations
is thus paramount in avoiding hospitalisation and its associated
costs, as well as in improving health-related quality of life.
Description of the intervention
The cornerstone of asthma exacerbations is airway inflammation,
often triggered by respiratory virus infection, allergen exposure
and/or respiratory irritants (Johnston 2006). This airway inflam-
mation sets up a vicious cycle of bronchial hyper-responsiveness
and mucus hypersecretion, leading to decreased expiratory flow.
Although short-acting beta agonists (SABA) often lead to rapid
reversal of airflow obstruction, they do not help the underlying in-
flammatory changes, so administration of systemic corticosteroids
is recommended in patients who have moderate to severe exacer-
bations and in those who fail to respond promptly to SABA treat-
ment (GINA 2015; NHLBI 2007).
Systemic corticosteroids have potent anti-inflammatory properties
and are the most effective drugs for suppressing the underlying in-
flammatory response in asthma exacerbations. In comparison with
placebo, they result in a faster rate of symptomatic improvement
(Fanta 1983), a significant reduction in the number of relapses and
decreased beta-2 agonist use (Rowe 2001) following an acute care
hospital visit for acute asthma. However, the well-recognised ad-
verse effects of repeated short courses of systemic corticosteroids,
including hyperglycaemia, psychiatric disturbance, adrenal sup-
pression and occurrence of severe varicella in children, provide the
rationale for an alternative management strategy such as use of
inhaled corticosteroids (McEvoy 2000). Furthermore, the strategy
of utilising short courses of oral prednisone for asthma exacerba-
tions, whether parent-initiated (Oommen 2003) or administered
in the acute care setting (Panickar 2009), has not proved effective
in pre-school-aged children.
How the intervention might work
Inhaled corticosteroids (ICS) have an established role in the man-
agement of chronic asthma. They are considered the most potent
and effective long-term controller medications for asthma (GINA
2015; NHLBI 2007). Clinical benefits of ICS in the management
of acute asthma are less well established because systemic corticos-
teroids are often relied upon as first-line therapy. Inhaled corticos-
teroids offer a theoretical advantage in the acute setting in that they
are delivered directly to the airways, thus maximising lung deposi-
tion and resulting in higher local potency and potentially faster on-
set of effect (Rodrigo 2006). A previous study demonstrated lower
bronchial eosinophilic inflammation within the first 24 hours in
participants randomised to high-dose inhaled fluticasone com-
pared with oral prednisone (Belda 2007). In a Cochrane review
comparing use of high-dose ICS versus systemic corticosteroids
for asthma exacerbations following discharge from the emergency
department (ED), review authors found no significant differences
in relapse rates, beta-2 agonist use or adverse events (Edmonds
2003). On the basis of these studies, high-dose ICS might offer a
promising alternative to oral corticosteroids.
Why it is important to do this review
With increasing recognition that early treatment of asthma ex-
acerbations is the best strategy for management, written action
plans to guide patient self management of exacerbations are rec-
ommended (GINA 2015; NHLBI 2007). Most patients with per-
sistent asthma are regular users of ICS; thereforemany action plans
based on consensus opinion initially advocated doubling the dose
of ICS as one of the first steps in treating or preventing progression
of exacerbations of asthma (Boulet 1999; BTS 1997). In the light
of lack of evidence to support this recommendation, recent guide-
lines have been more cautious (BTS/SIGN 2014; GINA 2015;
NHLBI 2007). We believe that publication of several clinical tri-
als offers an important opportunity to clarify further the role of
this strategy in home management of asthma exacerbations. We
prepared this update of the Cochrane review originally published
in 2010 (Quon 2010) to bring the evidence on this topic up-to-
date.
O B J E C T I V E S
To compare the clinical effectiveness and safety of increased versus
stable doses of inhaled corticosteroids as part of a patient-initiated
action plan for home management of exacerbations in children
and adults with persistent asthma.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full
text, those published as abstract only and unpublished data. We
included only double-blinded placebo-controlled trials to avoid
treatment bias with respect to activation of the asthma action plan
and determination of subjective treatment outcomes such as treat-
ment failure necessitating rescue systemic corticosteroids.
Types of participants
We included adults and children with asthma exacerbation as de-
fined by guideline criteria such as those outlined in GINA 2015,
or by a set of criteria pre-defined in the included studies. The di-
agnosis of asthma was confirmed by a physician before the time of
enrolment. Participants had to have taken a stable dose of ICS for
a minimum of two weeks before enrolment. We excluded studies
involving participants treated with continuous daily oral corticos-
teroids.
Types of interventions
We included studies that compared continuing a stable dailymain-
tenance dose versus increasing the daily dose of ICS as part of an
asthma exacerbation action plan. Active or placebo step-up ther-
apy was to be increased at home at or shortly after the onset of
symptoms signalling the beginning of an exacerbation. Other co-
interventions such as long-acting beta agonists, leukotriene modi-
fiers and other asthma medications were permitted, provided that
the dose remained unchanged throughout the study. The only ex-
ception to this was the allowance of increased short-acting beta
agonist use during exacerbations. Specifically, inhaled short-acting
beta agonists and short courses of systemic corticosteroids were
allowed as rescue medications.
Types of outcome measures
Primary outcomes
• Treatment failure - need for rescue systemic corticosteroids*
in all randomised participants (i.e. intention-to-treat (ITT)
analysis).
Secondary outcomes
• Treatment failure - need for rescue systemic corticosteroids*
in participants using the study inhaler.
• Unscheduled physician visits.
• Unscheduled acute care or emergency department visits or
need for hospital admission.
• Serious** and non-serious adverse events.
• Duration of exacerbation as defined by:
◦ recovery of lung function;
◦ recovery of symptoms; or
◦ beta-2 agonist use back to baseline.
*oral, intramuscular (IM) or intravenous (IV).
**Serious adverse events were defined as fatality, need for hospital-
isation, prolongation of hospitalisation, disability and study with-
drawal due to the adverse event. We noted in the analysis whether
definitions used within these studies differed.
Search methods for identification of studies
Electronic searches
We have detailed search methods used in the previous version
of this review in Appendix 1. The previously published version
included searches up to October 2009. The search period for this
update extended from October 2009 to March 2016.
For this update, we identified trials from the Cochrane Airways
Group Specialised Register (CAGR), which is maintained by the
Information Specialist for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative In-
dex to Nursing and Allied Health Literature (CINAHL), the
Allied and Complementary Medicine Database (AMED) and
PsycINFO, and by handsearching of respiratory journals and
meeting abstracts (please see Appendix 2 for further details). We
searched all records in the CAGR using the search strategy pre-
sented in Appendix 3.
We also conducted a search of ClinicalTrials.gov (http://
www.clinicaltrials.gov) and the World Health Organization
(WHO) trials portal (http://www.who.int/ictrp/en/) for ongoing
and unpublished trials. We searched all databases from their in-
ception to the present, with no restriction on language of publi-
cation. We conducted the latest search in March 2016.
Searching other resources
We updated additional searches of trial registries and grey liter-
ature databases to identify articles that might not have appeared
in the main electronic database searches. We searched pharma-
ceutical company clinical trial registries (AstraZeneca and Glax-
oSmithKline) and grey literature databases (Open System for In-
formation on Grey Literature in Europe (OpenSIGLE) and the
New York Academy of Medicine). Historical searches for previous
versions of this review included http://www.controlled-trials.com
and http://www.clinicalstudyresults.org, which we covered in the
new WHO trials portal and ClinicalTrials.gov searches. We also
checked reference lists of retrieved articles and reviews and asked
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field experts if they knew of any relevant ongoing or unpublished
trials.
Data collection and analysis
Selection of studies
Two review authors (MQ and KK for 2015 update, previously
BSQ and NS) independently screened titles and abstracts for in-
clusionof all potential studies identified as a result of the search and
coded them as ’retrieve’ (eligible or potentially eligible/unclear) or
’do not retrieve’. We retrieved full-text study reports/publications,
and two review authors (MQ and KK for 2015 update, previ-
ously BSQ and NS) independently screened the full-text studies
for inclusion, and identified and recorded reasons for exclusion of
ineligible studies. We resolved disagreements through discussion
or, if required, by consulting a third person (BSQ). We identified
and excluded duplicates and collated multiple reports of the same
study, so that each study rather than each report was the unit of in-
terest in the review. We recorded the selection process in sufficient
detail to complete a PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) flow diagram for Cochrane
systematic review updates (Stovold 2014) and Characteristics of
excluded studies tables.
Data extraction and management
We used a data collection form for study characteristics and out-
come data, which had been piloted on at least one study in the
review. Two review authors (MQ and KK for 2015 update, previ-
ously BSQ and NS) extracted the following study characteristics
from included studies.
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
• Notes: funding for trial, and notable conflicts of interest for
trial authors.
Two review authors (MQ and KK for 2015 update, previously
BSQ and NS) independently extracted outcome data from in-
cluded studies. We noted in the Characteristics of included studies
table if outcome data were not reported in a useable way. We re-
solved disagreements by reaching consensus or by involving a third
person (BSQ). One review author (KK) transferred data into the
Review Manager (RevMan 2014) file. We double-checked that
data were entered correctly by comparing data presented in the
systematic review with those provided in the study reports.
Assessment of risk of bias in included studies
Two review authors (MQ and KK for 2015 update, previously
BSQ and NS) independently assessed risk of bias for each study
using the criteria outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We resolved disagree-
ments by discussion or by consultation with another review au-
thor (BSQ). We assessed risk of bias according to the following
domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report, together with a jus-
tification for our judgement, in the ’Risk of bias’ table. We sum-
marised risk of bias judgements across different studies for each of
the domains listed.We considered blinding separately for different
key outcomes when necessary (e.g. for an unblinded outcome as-
sessment, risk of bias for all-cause mortality may be very different
than for a patient-reported pain scale). When information on risk
of bias was related to unpublished data or correspondence with a
trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to those outcomes.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review. We brought some
sections of the methods up-to-date for the most recent version of
the review.
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs), and contin-
uous data as mean differences (MDs) or standardised mean differ-
ences (SMDs). We entered data presented as a scale with a consis-
tent direction of effect.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
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When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A vs
placebo and drug B vs placebo) were combined in the same meta-
analysis, we halved the control group to avoid double-counting.
Unit of analysis issues
We pooled the results of parallel and cross-over studies when we
were satisfied that data could be appropriately analysed to account
for intercorrelation in cross-over studies. We analysed data using
participants with one or more events as the unit of analysis. For
dichotomous outcomes, when we did not know whether the num-
ber of events applied to the entire population or only to those tak-
ing the study inhaler, we used the total number randomised per
group as the denominator. We performed sensitivity analyses by
using the number of participants using their study inhaler at least
once as the denominator to test this assumption.
If no events were reported in control or treatment groups, we used
the Peto odds ratio to avoid use of the continuity correction.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as abstract only).
When this was not possible, and when missing data were thought
to introduce serious bias, we explored the impact of including
such studies in the overall assessment of results by performing a
sensitivity analysis.
Assessment of heterogeneity
We examined homogeneity of effect sizes between pooled studies
with the I2 statistic (Higgins 2003). In the absence of heterogene-
ity (I2 < 25%), we used the fixed-effect model (Greenland 1985);
otherwise we applied summary estimates and reported the Der-
Simonian and Laird random-effects model (DerSimonian 1986).
Unless otherwise specified, we reported the fixed-effect model, as
it is better equipped than the random-effects method to detect
small effect sizes (Fields 2001).
Assessment of reporting biases
We were not able to pool more than 10 trials; therefore we did not
create a funnel plot to explore possible small study and publication
biases.
Data synthesis
For dichotomous outcomes, we pooled parallel studies usingMan-
tel-Haenszel (M-H) ORs unless few events were reported, thus re-
quiring Peto odds ratios. We obtained ORs from cross-over stud-
ies by comparing the number of participants who needed oral
corticosteroids with increased dose (but not with placebo) versus
those who needed oral corticosteroids while taking placebo (but
not while taking increased ICS dose). We presented ORs with
95% confidence intervals (CIs). For continuous outcomes, such
as length of exacerbation, we calculated pooled statistics as MDs
and reported them with 95% CIs.
Summary of findings table
We created a ’Summary of findings’ table using the following out-
comes: rescue systemic corticosteroids (ITT analysis), treatment
failure as judged by the need for rescue systemic corticosteroids in
participants requiring the study inhaler (modified ITT analysis),
unscheduled physician visits, unscheduled acute care or ED visits
or hospital admissions, duration of exacerbations and serious ad-
verse events. We used the five GRADE (Grades of Recommenda-
tion, Assessment, Development and Evaluation Working Group)
considerations (study limitations, consistency of effect, impreci-
sion, indirectness and publication bias) to assess the quality of a
body of evidence as it relates to studies that contributed data to
meta-analyses for pre-specified outcomes. We used methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) perGRADEpro software.We justified all decisions to down-
grade or upgrade the quality of studies by using footnotes, and we
made comments to aid readers’ understanding of the review when
necessary.
Subgroup analysis and investigation of heterogeneity
Weplanned the following a priori subgroup analyses of the primary
outcome to identify potential effect modifiers, irrespective of the
presence or absence of heterogeneity.
• Age group (children < 15 years old vs adults ≥ 15 years old).
• Smoking status (smokers vs ex-smokers or never-smokers).
• Time elapsed before initiation of treatment (< 48 hours vs
≥ 48 hours).
• Maintenance ICS dose (ex-valve) before increase (low vs
moderate vs high*).
• Achieved daily dose of ICS (ex-valve) during exacerbation
(low vs moderate vs high*).
• Fold increase in baseline ICS dose during exacerbation
(double dose vs quadruple dose).
In the previous version, subgroup analyses were repeated post hoc
for the secondary outcome of treatment failures only within those
who started the study inhaler. In this version, we conducted sub-
group analyses only on the primary outcome alone.
*ICS dose was classified according to Global Initiative for Asthma
Guidelines (GINA 2015) as follows.
• High dose - adults: > 1000 mcg/d of chlorofluorocarbon-
propelled beclomethasone dipropionate (CFC-BDP) dose or
equivalent. Children: > 400 mcg/d equivalent CFC-BDP dose.
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• Moderate dose - adults: > 500 mcg to 1000 mcg/d CFC-
BDP equivalent. Children: > 200 mcg to 400 mcg/d CFC-BDP
equivalent.
• Low dose - adults: 200 mcg to 500 mcg/d CFC-BDP
equivalent. Children: 100 mcg to 200 mcg/d CFC-BDP
equivalent.
Fluticasone propionate was converted to CFC beclomethasone
dipropionate (CFC-BDP) equivalents by multiplying the ex-valve
dose by two because its reported potency in asthmatic patients
is two-fold relative to CFC-BDP (Barnes 1993). Budesonide was
converted to CFC-BDP equivalents by multiplying the ex-valve
dose by 1.25, as reported in the Canadian Asthma Guidelines
(Lemiere 2003).
Sensitivity analysis
We planned the following sensitivity analyses for the primary out-
come.
• Study design (removing cross-over studies).
• Methodological quality (removing studies at high risk of
selection bias).
• Source of study funding (removing studies funded by
pharmaceutical companies).
R E S U L T S
Description of studies
Results of the search
The main electronic database update search for October 2009 to
March 2016 returned 436 records. We searched 699 additional
records found in other resources (365 fromAstraZeneca, 164 from
GlaxoSmithKline, 143 from clinicaltrials.gov, 24 from the WHO
trials portal, one from the New York Academy of Medicine, one
fromOpenSIGLE andone from study reference lists).We screened
all 1135 records and excluded 1119 by looking at the titles and
abstracts alone. We reviewed the full texts for 16 records and ex-
cluded 13 that did not meet the inclusion criteria. We included
three new studies that met the criteria for this review. For the pre-
vious version of this review, which covered up to October 2009,
review authors screened the titles and abstracts of 882 records, as-
sessed full texts for 39 that were potentially relevant and included
five trials that met the inclusion criteria. Together with the three
new studies, a total of eight studies met the inclusion criteria for
this review. Results of the update search are shown in Figure 1,
along with the number of studies brought forward from the pre-
vious version (Stovold 2014).
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Figure 1. Study flow diagram.
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Included studies
This review update added three new studies including 419 par-
ticipants to the review. In total, eight studies met the eligibility
criteria: five adult (Fitzgerald 2004; Foresi 2000; Harrison 2004;
Oborne 2009; Rice-McDonald 2005) and three paediatric studies
(Garrett 1998; Martinez 2011; Wainwright 2009). All were pub-
lished as full-text papers with the exception of Wainwright 2009,
for which study details and results were provided by the lead inves-
tigator. The eight studies randomised a total of 1669 participants
to the comparison of interest for this review. Of all randomised
participants, 58.5% had an exacerbation that led to use of the
study inhaler. Four of the eight studies were multi-centre and four
were single-centre studies. Three were conducted in Australasia,
three in Europe and two in North America. The mean number
of people randomised to treatment groups relevant to this review
was 208 (range 22 to 403).
All included trials compared the efficacy of an increased dose of
ICS at the onset of an exacerbation versus placebo as part of an
asthma action plan. All other medications, mainly rescue short-
acting beta agonist inhalers, were kept equal between treatment
and placebo groups and are noted in individual study characteris-
tics tables.
Details of the countries and centres inwhich trials were conducted,
sample sizes and the percentage with exacerbations in each trial,
study treatments, durations and funding are shown in Table 1.
Wedescribe hereafter the characteristics of studies that contributed
data to one or more outcomes in the review. For a full study
description of each eligible study, see Characteristics of included
studies.
Characteristics of studies
Run-in
All eight studies included a run-in period from two weeks to three
months, mainly to ensure asthma stability. Three adult studies re-
cruited participants who required low to moderate maintenance
doses at baseline, ranging from amean of 520 mcg/d to 710 mcg/d
ofCFC-BDPequivalent (Fitzgerald 2004;Harrison 2004;Oborne
2009). The two other adult studies (Foresi 2000; Garrett 1998)
and the three paediatric studies did not report the mean main-
tenance ICS dose at baseline. In all studies except Foresi 2000,
participants continued their usual maintenance dose during the
run-in period. Foresi 2000 required a temporary increase in ICS
dose to 1600 mcg/d for four weeks during run-in, with reduction
back to 200 mcg/d after randomisation.
Study design
Six of the eight studies had parallel-group designs comparing peo-
ple whowere given a placebo inhaler or an active inhaler to increase
their ICS dose during exacerbations. Garrett 1998 was a cross-over
design whereby children were randomised to one of two possible
treatment sequences for serial exacerbations: placebo then corti-
costeroid, or corticosteroid then placebo. Rice-McDonald 2005
also used a cross-over design with three treatment phases, one of
which was not relevant to this review (oral steroid rescue). For
this study, we used results from the paper showing the number of
people who needed oral steroids in one, neither or both of the two
relevant phases, and analysed them to account for correlation.
Study duration
Duration of follow-up for exacerbations post randomisation was
six months for three studies (Fitzgerald 2004; Foresi 2000; Garrett
1998), 44 weeks for one study (Martinez 2011) and 12months for
three studies (Harrison 2004; Oborne 2009; Wainwright 2009).
The duration in Rice-McDonald 2005 was unclear, although in-
vestigators stated that the endpoint for each treatment was assessed
seven days after the three-week treatment pack if no treatment
failure, or at time of treatment failure in the event of failure.
Characteristics of participants
Age
Four of the five adult studies recruited people from age 16 or 18
years of age onwards, andFitzgerald 2004 also included adolescents
from the age of 13 years. Mean participant age in the adult studies
ranged from 32 to 56 (median 46.5) years. The age range in the
paediatric studies ranged from six to 14 years (Garrett 1998), from
six to 18 years (Martinez 2011) and from three to 14 years (
Wainwright 2009). Mean participant ages were 8.2 and 11.2 years
inGarrett 1998 andMartinez 2011, respectively, andwe calculated
a rough mean age from that categorised in Wainwright 2009 as
7.6 years.
Gender
All studies included both male and female participants. All adult
studies included more women than men (median percentage male
33%, range 28% to 47%), and all paediatric studies recruited
more boys than girls (median percentage male 60%, range 57%
to 67%).
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Smoking status
Four of the eight trials reported the smoking status of study partic-
ipants. Never-smokers made up most of the study samples (61%
to 86%), with ex-smokers making up between 14% and 36%, and
active smokers 10% or less of the samples. Rice-McDonald 2005
and the three paediatric studies did not report smoking status.
Severity
Baseline asthma severitywas explicitly stated in just two studies and
was reported as mild to moderate in Garrett 1998 and moderate
in Foresi 2000. The remainder of studies reported baseline asthma
severity as lung function measurements during the stable run-
in period, or informally by minimum medication requirements,
which are summarised in the final column of Table 1. The average
severity of airway obstruction was mild (forced expiratory volume
in one second (FEV1) > 80%) inHarrison 2004 andOborne 2009.
Fitzgerald 2004 reported amean baseline FEV1 of 2.8 L and a peak
expiratory flow rate (PEFR) of 423 L/min, also falling within the
mild severity category. Two paediatric studies - Rice-McDonald
2005 andWainwright 2009 - required children tohave had a recent
admission or course of oral steroids for an asthma exacerbation.
Rice-McDonald 2005 excluded people with mild asthma.
Treatment format
Study treatment details
In all eight studies, participants were required to be taking a stable
dose of ICS at randomisation, with the dose of ICS increased
at the onset of an asthma exacerbation, compared with placebo.
In all studies, this was achieved with a study inhaler to be taken
alongside the maintenance inhaler that contained additional ICS
or placebo, administered at home by participants themselves, or
with the aid of a parent or carer for younger children. The dose was
increased five-fold in Foresi 2000 and four-fold in Oborne 2009
and was doubled in the remaining six studies (Fitzgerald 2004;
Garrett 1998; Harrison 2004; Martinez 2011; Rice-McDonald
2005; Wainwright 2009). The mean ICS dose achieved during
exacerbations ranged from 1000 mcg/d to 2075 mcg/d in CFC-
BDPequivalents in the adult studies (Fitzgerald 2004; Foresi 2000;
Harrison 2004; Oborne 2009) and from 160 to 500 mcg/d in the
paediatric studies (Martinez 2011; Wainwright 2009). Mean dose
achieved was not reported in the paediatric study of Garrett 1998,
although the maximum dose achieved was 1600 mcg/d. Studies
used metered dose or dry powder inhalers, but within studies the
treatment or placebo inhaler provided for use during exacerbation
was identical to themaintenance corticosteroid inhaler.Moreover,
the additional use of a spacer was reported in Garrett 1998 and
Wainwright 2009. Inhaled corticosteroid dose was increased for a
pre-defined period of 14 days in Fitzgerald 2000, Harrison 2004
and Rice-McDonald 2005. In Garrett 1998, it was increased for
just three days, in Foresi 2000 for seven days and in Oborne 2009
for just seven days if PEFR had returned to baseline by then, but
was continued for 14 days if PEFR had not returned to baseline
by day seven. In Martinez 2011, Oborne 2009 and Wainwright
2009, the course of increased ICS dose varied depending on how
long it took for symptoms to return to baseline.
Action plan activation
Criteria for an asthma exacerbation that prompted initiation of
the study inhaler were pre-defined in all studies on the basis of a
combination of PEFR worsening, increase in asthma symptoms
and/or an increase in rescue bronchodilator use relative to run-in
values. In all eight studies, participant measurements or observa-
tions obtained alone or with confirmation from a study physician
were required for activation of the asthma action plan at the onset
of an asthma exacerbation. Participants were required to measure
PEFR, to record asthma symptoms and/or tomonitor rescue bron-
chodilator use continuously, or if they believed that their asthma
control was deteriorating.One study used aPEFR cut-off of < 85%
of baseline in the criteria of an exacerbation (Harrison 2004), four
studies used a cut-off of PEFR < 80% (Fitzgerald 2004; Garrett
1998; Martinez 2011; Rice-McDonald 2005) and one study used
a cut-off of < 70% (Foresi 2000). Oborne 2009 used a variable
PEFR cut-off of < 85% of baseline on two consecutive days, or <
70% of baseline on a single day, andWainwright 2009 did not de-
fine a cut-off. All studies incorporated an increase in asthma symp-
toms into the criteria of an exacerbation. Three studies incorpo-
rated an increase in rescue bronchodilator use among the criteria of
an exacerbation (Fitzgerald 2004; Garrett 1998; Rice-McDonald
2005). All studies provided clear criteria for asthma action plan ac-
tivation. The minimum time elapsed between onset of asthma de-
terioration and initiation of increased ICS dose (as recommended
by the action plan) varied from immediate use of the study inhaler
as a rescue treatment (Martinez 2011; Wainwright 2009) to 24
hours after symptoms worsened (Garrett 1998; Harrison 2004;
Rice-McDonald 2005) to 48 hours (Fitzgerald 2004; Foresi 2000).
For Oborne 2009, elapsed time varied from 24 hours to 48 hours,
depending on how much PEFR had dropped from baseline.
Concomitant treatment
In all included studies, baseline co-interventions for asthma were
continued, provided that the dose remained unchanged through-
out the study period. Four studies permitted the use of long-acting
beta agonists (LABA), and two studies explicitly stated that pa-
tients requiringLABAbefore study entrywere excluded (Fitzgerald
2004; Garrett 1998). Martinez 2011 and Wainwright 2009 did
not report whether any of the recruited participants were currently
taking LABA. Martinez 2011 did report that a small number had
taken LABA in the previous year (6% and 4%), and reported us-
age rates in Harrison 2004 and Oborne 2009 of about 40% in
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control and treatment groups. One study (Fitzgerald 2004) re-
ported on inclusion of participants requiring oral theophylline at
baseline, although usage rates were low at less than 4%, and an-
other study reported on inclusion of participants requiring regular
ipratropium at baseline (Fitzgerald 2004). Rice-McDonald 2005
allowed concomitant use of LABA, theophylline or leukotriene
receptor antagonists but did not report the number of participants
taking them at baseline. Baseline nasal ICS use was reported in
Fitzgerald 2004, with usage rates of 25% and 26% for control and
treatment groups, respectively.
Treatment follow-up
After the action plan was initiated, study investigators provided
variable follow-up periods. In Garrett 1998, participants were
visited within the first three days at home and then were seen
within one week in the clinic. Fitzgerald 2004 reported post-
treatment surveillance for a period of three months to monitor
asthma control and to ensure no late differences between treatment
and placebo groups. Wainwright 2009 conducted three-monthly
routine check-ups, contacted participants two weeks after each
exacerbation and took final measurements after 12 months. In
Rice-McDonald 2005, a cross-over study, participants were con-
tacted fortnightly by a research nurse and were reviewed by a study
investigator every eight weeks. Martinez 2011 reviewed partici-
pants every four to eight weeks over the 44-week study period,
regardless of exacerbations. Medical follow-up after the exacerba-
tion was not described in Foresi 2000, Harrison 2004 and Oborne
2009.
Action plan compliance
Four studies monitored compliance with symptom recording and/
or study treatment (Fitzgerald 2004; Foresi 2000; Garrett 1998;
Rice-McDonald 2005). Investigators evaluated complianceby re-
viewing self reported symptom diaries, self reported medication
diaries and PEFR recordings and by counting tablets from re-
turned treatment packs. Self reported study treatment compli-
ance was high in three studies, ranging from a mean of 86% in
Garrett 1998 to 93% in Fitzgerald 2004, and was not reported in
Rice-McDonald 2005.
Upfront oral corticosteroid use
Participants were required to start oral corticosteroids upfront at
the onset of an asthma exacerbation if PEFR was measured at less
than 60% in four studies (Fitzgerald 2004;Garrett 1998; Harrison
2004; Oborne 2009) and 50% in one study (Foresi 2000).
Outcome reporting
The primary outcome for this review - the need for rescue systemic
corticosteroids - was reported in all studies except Foresi 2000.
Generally participants were withdrawn from use of the study in-
haler and were started on rescue oral corticosteroids if they failed
to respond adequately to an increase in ICS dose, or if their PEFR
dropped to below a pre-defined safety cut-off (usually 60%). Treat-
ment failure was defined by deterioration or lack of improvement
in pulmonary function and/or symptoms. Rescue oral corticos-
teroids were participant-initiated if PEFR fell below a pre-defined
threshold of 60% at any point during the treatment period, or af-
ter discussion with a study physician based on symptom frequency
and PEFR measurements. Harrison 2004 and Oborne 2009 re-
quired rescue oral corticosteroid use if participants’ asthma con-
trol deteriorated to the point that they would usually start oral
corticosteroids.
Pre-defined secondary outcomes were reported less consistently
across studies, with no more than three studies included in any of
the secondary analyses.
Excluded studies
Reasons for exclusion of 39 studies, including those excluded in
the previous version and those excluded in the current update,
are documented in the Characteristics of excluded studies section.
Of 13 records related to nine studies excluded in this update,
the most common reasons for exclusion after viewing of full texts
were that ICS were not being given to treat an exacerbation of
asthma (N = 6) and no arm was receiving stable ICS (N = 4). Two
records were related to a study that was already included in the
previous version of this review (Oborne 2009), and one described
an ongoing study (NCT02066129). Of the 34 records related to
30 excluded from the previous version of this review, reasons for
exclusion included that trials were not placebo-controlled (N =
15), did not recruit people with asthma (N = 1), did not test
ICS to treat an exacerbation (N = 4) and did not recruit people
taking maintenance ICS (N = 13). One remaining study that was
listed as excluded in the previous version of this review was moved
from excluded to included in this update (Rice-McDonald 2005).
The reason for exclusion was that available data did not allow for
analysis and study authors could not be contacted for clarification;
we were able to rectify this in the current version.
Risk of bias in included studies
We have presented in Figure 2 an overview of the risk of bias in
individual studies.. In general, all trials were of high methodolog-
ical quality and had low risk of bias.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study
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Allocation
Five of the eight studies gave sufficient detail regarding random
sequence generation to be considered at low risk of bias, stating that
computer-generated codes or random number tables were used
(Fitzgerald 2004; Harrison 2004; Martinez 2011; Oborne 2009;
Wainwright 2009). We did not have sufficient information from
the remaining three studies, which were rated as having unclear
risk.
For concealment of the allocation, we considered all except Foresi
2000 to be at low risk of bias because details given suggested
that randomisation was done through a central system or by an
independent pharmacist not otherwise involved in the study.
Blinding
Seven studies explicitly stated their double-blind design andmask-
ing procedures and therefore were at low risk of bias. Wainwright
2009 was not described as double-blind, but investigators de-
scribed matching placebo inhalers, which implies that blinding
procedures were used; hence we also considered this study to be
at low risk of bias.
Incomplete outcome data
We considered five studies to be at low risk of bias as the result of
incomplete data. Withdrawal rates in Fitzgerald 2004, Martinez
2011 and Oborne 2009 ranged between 11% and 22% across
groups, but rates were fairly balanced within studies and appropri-
ate imputation was used to adhere to the ITT principle. Dropout
was not given per group in Foresi 2000, but overall dropout was
low (10.6%) and the ITT analysis included 98% of those ran-
domised. Garrett 1998 was rated as having low risk because, al-
though several participants were not included in their analyses,
this occurred because of their cross-over design and as a result of
their plan to include only participants who had exacerbations in
both study phases.
Harrison 2004 was rated as having unclear risk because, although
around 10% dropped out of each group, which is a relatively
low and balanced dropout rate, investigators did not make clear
whether they had used the protocol or ITT analyses. We rated
Rice-McDonald 2005 as having high risk of bias because 13 of the
35 people randomised (37%) dropped out and were not included
in the analysis.
Selective reporting
Wewere satisfied that no selective outcome reporting had occurred
in seven included studies, either because stated outcomes were well
defined and reported in the published papers after study authors
provided additional data upon request, or because we were able to
confirm with study authors that the outcomes we were interested
in had not been measured. We rated none of the studies as having
high risk of bias and only one as having unclear risk for these
reasons.
Other potential sources of bias
The cross-over study by Garrett 1998 did not state the time
lapse between treatments and did not comment on any possible
carry-over effect. If the effective intervention is followed closely
by placebo, the therapeutic effect could be carried over into the
placebo period, thereby minimising any possible differences be-
tween placebo and treatment.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcome
Treatment failure - need for systemic corticosteroids (ITT
analysis)
People randomised to an increased ICS dose during an exacerba-
tion were not significantly less likely to require rescue oral cor-
ticosteroids compared with those assigned to placebo (OR 0.89,
95% CI 0.68 to 1.18; participants = 1520; seven studies; I2 = 0%;
Analysis 1.1). Just under 60% of randomised participants actu-
ally required use of the study inhaler (mean 58.5%, range 23%
to 100%). The estimate slightly favoured increased ICS dose, but
confidence intervals did not rule out the possibility that keeping
the dose stable was better, so we downgraded the evidence once
for imprecision and rated the study as having moderate quality.
Subgroup analysis
When the primary outcome was used with all randomised partici-
pants as the analysis denominator, five out of six subgroup analyses
had sufficient data for analysis. Findings of tests for subgroup dif-
ferences in age (Analysis 2.1), time to treatment initiation (Analysis
2.2), maintenance ICS dose (Analysis 2.3) and exacerbation ICS
dose (Analysis 2.4) were all non-significant. Garrett 1998 could
not be included in maintenance or achieved ICS dose subgroups
because of the large dose range, which included no details about
average doses on which to base a categorisation. The estimate
favoured an ICS increase more if the dose was quadrupled rather
than doubled, but only one study quadrupled the dose, and the
difference between dose subgroups was not statistically significant
(I2 = 47, P value = 0.17). We could not examine the impact of
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smoking status on the odds of requiring oral corticosteroids dur-
ing an exacerbation because all studies recruited non-smokers or
ex-smokers.
Sensitivity analysis
Study design
Removing the two cross-over studies (Garrett 1998 and Rice-
McDonald 2005) from the primary analysis had very little effect
on direction, size or precision of the estimate size for the primary
outcome (OR 0.87, 95% CI 0.66 to 1.16; Analysis 2.6).
Methodological quality
The two cross-over studies were the only studies with uncertainties
regarding risk of selection bias, so the result was the same as for
the study design sensitivity analysis above.
Source of study funding
Three studies were funded by pharmaceutical companies involved
in the sales of ICS (Fitzgerald 2004; Foresi 2000; Garrett 1998).
Fitzgerald 2004 and Garrett 1998 contributed data to the primary
outcome. Their exclusion slightly increased the size of the effect
in favour of increasing ICS dose and the precision of the estimate,
but it did not alter the conclusions drawn (OR 0.84, 95% CI 0.62
to 1.12).
Publication bias
Studies were too few for review authors to determine whether
publication bias was present or to identify a systematic difference
between smaller and larger studies via funnel plot analysis.
Secondary outcomes
Asthma exacerbations requiring rescue systemic
corticosteroids (modified ITT analysis)
We included the same seven studies in this outcome (Fitzgerald
2004; Garrett 1998; Harrison 2004; Martinez 2011; Oborne
2009; Rice-McDonald 2005;Wainwright 2009), when looking at
the effect of doubling ICS in participants who took their study
inhaler rather than all those randomised. In two studies, all ran-
domised participants took their study inhaler, so the data were
the same as those entered for the primary outcome. The analysis
included 766 people who had exacerbations meeting the study
criteria rather than all 1520 randomised to the studies. Significant
inconsistency between study results also contributed to impreci-
sion in the estimate, meaning that the evidence was considered of
low quality. The pooled estimate did not suggest that participants
randomised to increase their ICS dose were less likely to require
rescue systemic corticosteroids compared with those assigned to
placebo (OR 0.84, 95%CI 0.54 to 1.30; participants = 766; seven
studies); I2 = 42%; random-effects method; Analysis 1.2).
We did not perform subgroup and sensitivity analyses on this
outcome as was done in the previous version of the review, as these
analyses were not originally planned in the protocol.
Unscheduled physician visits
Three parallel-group studies measured this outcome and showed
no significant differences in the odds between groups (OR 0.96,
95% CI 0.66 to 1.41; participants = 931; three studies; I2 = 0%;
Analysis 1.3). Harrison 2004 and Wainwright 2009 reported un-
scheduled visits only for people who took their study inhaler, but
we used the total number randomised as the denominator. We
performed a post hoc sensitivity analysis using only those taking
the study inhaler as the denominator for these two studies, and
our conclusions did not change (OR 0.89, 95% CI 0.59 to 1.35).
The width of the confidence intervals made it very difficult to
determine where the true effect may lie, so we downgraded the
evidence twice for imprecision and rated the studies as low quality.
Unscheduled acute care or emergency department visits or
need for hospital admission
Three studies collected data on unscheduled acute care or emer-
gency department visits, but only one paediatric study observed
any events (Wainwright 2009). We could not draw a meaningful
conclusion because the study estimate was based on only four vis-
its in either group (Peto OR 0.98, 95% CI 0.24 to 3.98; partic-
ipants = 450; three studies), and we downgraded the evidence to
low for this imprecision. It made very little difference when only
the number taking the study inhaler was used as the denominator
(Peto OR 1.01, 95% CI 0.25 to 4.15; participants = 386; three
studies).
Duration of exacerbation
Three studies reported data on the duration of exacerbation fol-
lowing initiation of study inhaler, as defined by the time required
for PEFR to return to baseline values (Garrett 1998; Harrison
2004; Oborne 2009). However, group mean and standard devi-
ation values were available only for Harrison 2004 and show no
benefit for recovery time with increased ICS (Analysis 1.5).
Two studies provided data on the duration of exacerbation fol-
lowing initiation of study inhaler, as defined by time required for
symptoms to return to baseline values (Fitzgerald 2004; Harrison
2004). Again, only mean and standard deviation values were re-
ported (Harrison 2004), and results show no benefit of increased
ICS when this definition was used (also in Analysis 1.5).
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Imprecision in both estimates made it difficult for review authors
to be certain of the true effect, so we downgraded both once for
imprecision and rated the studies as moderate quality.
No studies reported data for the duration of exacerbations defined
as reduction in beta2 agonist use back to baseline requirements.
Serious and non-serious adverse events
Participants assigned to an increased ICS dose following onset of
an asthma exacerbation did not have significantly more serious
adverse events (OR 1.69, 95%CI 0.77 to 3.71; participants = 394;
two studies). Serious adverse events in Martinez 2011 included
bronchitis in the increased dose group and viral meningitis in the
stable daily dose group.We classified study-defined serious adverse
events in Wainwright 2009 as follows, some of which might not
generally be considered serious adverse events: upper respiratory
tract infection/otitis media/croup (six in double-dose group), ear/
nose/throat surgery (one in usual dose group, three in double-
dose group), fracture (one in usual dose group), other orthopaedic
events (one in each group), chest infection/pneumonia (four in
each group), other (three in usual dose group, two in double-dose
group) and death (one in double-dose group). The only serious
adverse events, whichwere reported inRice-McDonald 2005,were
noted in the oral steroid rescue group, which was not included in
this review.
Taking increased ICS did not significantly increase the odds of
having any non-serious adverse event (OR 2.15, 95% CI 0.68
to 6.73; participants = 142; two studies) compared with keep-
ing the dose stable. We have summarised specific non-serious ad-
verse events narratively because they were reported inconsistently
across studies. Three studies reporting lists of specific side effects
generally showed low occurrence (one or two people) in either
group (Foresi 2000; Oborne 2009; Rice-McDonald 2005). The
odds of occurrence of specific adverse effects including oral ir-
ritation, headaches, psychiatric disturbance, gastrointestinal dis-
comfort, dysphonia and change in appetite were not significantly
higher in the increased ICS versus stable dose groups. Results of
Rice-McDonald 2005must be interpreted with caution because of
the study’s cross-over design and the oral steroid treatment phase,
which was not included in this review.
Adverse events were not reported in detail in Fitzgerald 2004,
but the participant flow diagram showed that one person in the
double-dose group and three in the stable dose group dropped
out because of unspecified adverse events, none of whom had
exacerbations requiring the need for the study inhaler. Garrett
1998 andHarrison 2004 providedminimal information regarding
adverse events, although Garrett 1998 stated that no child was
hospitalised during the study (for asthma or for other reasons).
In addition to the data on serious adverse events, the Martinez
2011 paediatric study reported linear growth but not specifically
for the two groups compared in this review.
D I S C U S S I O N
Summary of main results
This review update added to the review three new studies includ-
ing 419 participants. In total we identified eight randomised con-
trolled trials (RCTs), most of which were at low risk of bias involv-
ing 1669 participants with mild to moderate asthma. We identi-
fied three paediatric (n = 422) and five adult (n = 1247) studies;
six were parallel-group trials, and two had a cross-over design; all
but one study followed participants for six months to one year. Al-
lowed maintenance doses of inhaled corticosteroids (ICS) varied
in adult and paediatric studies, as did use of concomitant medica-
tions and achieved ICS doses initiated during exacerbations. In-
vestigators gave participants a study inhaler containing additional
ICS or placebo to be started as part of an action plan to treat ex-
acerbations.
Available evidence suggests that an increased ICS dose was not
associated with a statistically significant difference in the odds of
needing rescue oral corticosteroids or in other effectiveness out-
comes compared with a continued stable dose of ICS. Subgroup
analyses of the primary outcome based on age (children vs adults),
time elapsing before treatment initiation (< 48 hours vs ≥ 48
hours), baseline ICSdose andmagnitude of the dose increase (dou-
bling vs quadrupling) showed no significant differences between
subgroups. The modified intention-to-treat analysis, with the de-
nominator restricted to participants who used the study inhaler for
at least one exacerbation to mimic an efficacy study, still failed to
demonstrate any overall benefit. The post hoc subgroup analysis
performed on the modified intention-to-treat analysis of the pri-
mary outcome suggested but did not confirm greater benefit with
quadrupling over doubling the ICS dose, as no head-to-head com-
parison of different ICS dose fold increase and no dose increase
were associated with a statistically significant reduction in odds. As
the subgroup analysis was based on themagnitude of dose increase
(doubling or quadrupling) rather than on absolute dose increase
or absolute dose achieved, it remains unclear whether magnitude
of dose increase or absolute dose increase/achieved would have
greater impact, if any, on apparent benefit. Whilst the apparent
benefit could be explained by the absence of a significant reduction
in odds, under-powering of the primary analysis due to inclusion
of participants who never used the study drug, known limitations
of subgroup analyses (particularly post hoc) and multiple statis-
tical testing require care in interpretation of this finding (Wang
2007). The comparative benefit of ICS dose-doubling versus qua-
drupling would be best examined by a head-to-head comparison
in a large RCT.
Confidence intervals around the primary outcome estimate for the
seven studies were wide; therefore one cannot exclude a possible
reduction or increase by about 30% in the odds of requiring res-
cue oral corticosteroids associated with increased ICS dosing. For
secondary outcomes, the ICS dose increase did not significantly
19Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reduce the frequency of unscheduled physician visits or unsched-
uled acute care visits or hospital admissions, although the effect es-
timates were imprecise. Studies were insufficient for aggregation of
data on other secondary outcomes, including duration of asthma
exacerbation as defined by return of lung function, symptoms or
rescue bronchodilator use back to baseline.
Participants allocated to an increased ICS dose during exacerba-
tions did not experience a statistically significant increase in the
odds of serious and overall or specific non-serious side effects,
namely, headaches, dysphonia, pharyngitis, glossitis, oral candidi-
asis, change in appetite, upper respiratory tract infection, psychi-
atric disturbance (depression, anxiety) and gastrointestinal symp-
toms (nausea and abdominal discomfort). Moreover, with the ex-
ception of linear growth (Martinez 2011), prospective data on
specific adverse events were not collected, likely leading to under-
reporting of adverse events. No studies reported data on the num-
ber of people experiencing hyperglycaemia, adrenal dysfunction
or pneumonia.
Overall completeness and applicability of
evidence
To our knowledge, this is the update of the only systematic review
and meta-analysis in the literature examining the safety and effec-
tiveness of increasing versus maintaining the same ICS dose at the
onset of an asthma exacerbation as part of a patient-initiated action
plan. Since this review was first published, the Global Initiative for
Asthma (GINA) Guidelines have been updated and no longer rec-
ommend temporary doubling of the ICS dose (GINA 2015). Our
results contrast with those of a pre-school trial demonstrating that
risk of the need for rescue systemic corticosteroids was reduced by
half when high-dose fluticasone versus placebo was used as a pre-
emptive strategy in children with viral-induced asthma, although
none of these young children were using daily ICS (Ducharme
2009).
Lack of overall benefit from an increased ICS dose strategy demon-
strated in this systematic reviewmight be explained in several ways.
First, regular use of ICS in asthma has proved very effective in pre-
venting exacerbations and specifically reducing the need for rescue
oral corticosteroids (Adams 1999): Daily ICS may indeed be the
most effective preventive strategy with minimal additional benefit
of pre-emptive increased ICS dose during exacerbations. For ex-
ample, just one-half of participants randomised in the included
studies required step-up therapy with the study inhaler. This low
exacerbation rate in turn may have led to possible under-powering
of data to detect a significant difference in odds between groups, if
present. Second, the small number of studies contributing data to
this outcome led to wide confidence intervals for most outcomes,
attesting to the lack of power to conclude firmly on the absence of
beneficial effect. Third, despite low heterogeneity between stud-
ies on the main outcome, participant, treatment or design char-
acteristics could have influenced the magnitude of effect, which
could not be adequately explored because of the small number of
studies. Finally, although self reported compliance with the action
plan protocol and study inhaler was high (86% in Garrett 1998,
100% in Fitzgerald 2004), actual compliance was not measured
and may have been lower. Indeed, in a previous study looking at
asthma action plan compliance in a family practice setting, less
than 40% properly implemented their action plan (Turner 1998).
In other words, included studies were primarily effectiveness trials;
consequently absence of effect may be due to non-efficacy or to
poor or delayed implementation of the intervention, which was
documented only by participant reports rather than as an objective
measure of adherence.
With regards to applicability of the findings, most data were de-
rived from non-smoking adults with mild to moderate asthma
who were taking low to moderate stable doses of ICS at baseline,
in addition to other asthma therapy. Study results may not apply
to children and adolescents, as just two included studies involved
children (Garrett 1998; Wainwright 2009) and one accepted an
unspecified number of adolescents.
Quality of the evidence
According to the GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation Working Group) method,
our confidence in the evidence across outcomes was moderate or
low, meaning that true effects may be substantially different from
pooled estimates. The most common limitation across outcomes
was lack of precision, which was a result of the small number of
identified studies and observed events. None of the outcomes were
thought to be compromised by risk of bias within studies; although
some uncertainties regarding allocation concealment and missing
data imputation were evident in some studies, review authors did
not deem this significant enough to have had a serious impact
on the results. Similarly, although we noted that several trials did
not contribute to secondary outcomes, contact with study authors
confirmed that this was unlikely to be due to publication bias. We
did not downgrade any of the outcomes because of indirectness of
study populations, interventions or outcomes for the review ques-
tion. At least two review authors made study inclusion decisions to
ensure that studies were relevant to the review, and resolved with
study authors any uncertainties in the definitions of outcomes.
Our confidence in the primary outcome was reduced from high
to moderate because the confidence interval around the null ef-
fect did not exclude the possibility of appreciable benefit of either
option. This imprecision affected our confidence both when the
need for oral steroids was assessed as a proportion of the total in-
tention-to-treat population, and when assessment was limited to
those starting their study inhaler. However, statistical heterogene-
ity in the latter analysis was much higher, so our confidence in this
analysis was low.
Within secondary outcomes, our confidence in the effect of in-
creasing ICS dose on unscheduled physician visits and unsched-
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uled acute visits was low, and was reduced substantially by the
numbers of studies and events included in the analyses. We also
judged the effect of increasing ICS dose on duration of exacerba-
tion and serious and non-serious adverse events as low because of
imprecision of the estimates.
Potential biases in the review process
The main strength of this review is its low opportunity for bias.
Although one cannot firmly rule out publication bias, our system-
atic search of published trials and unpublished reports was un-
dertaken with a high likelihood of identifying all relevant studies,
thus minimising this type of bias. Indeed, we found no abstracts
whose results were not published afterwards. The rigorous eligi-
bility criteria requiring double-blinding resulted in the inclusion
of generally high-quality trials, further strengthening the validity
of our findings.
This systematic review had a few limitations that could have in-
troduced bias. Inherent to the cross-over design of included stud-
ies, individual participants experienced multiple exacerbations/
treatments within the same study. Potential non-independence of
events due to inadequate wash-out may have resulted in undue
influence on study results in one direction or another. To obviate
to the issue of non-independence, all analyses were performed per
participant, not per event. Second, the limited response of study
authors or sponsors to requests for providing data contributed to
lack of precision for our primary outcome.
Agreements and disagreements with other
studies or reviews
We have identified no other non-Cochrane reviews addressing the
efficacy of increasing the dose of inhaled corticosteroids at the
onset of an asthma exacerbation as part of a patient-initiated action
plan. This is an update of a Cochrane review first published in
2010 (Quon 2010). We included in this review three additional
studies (Martinez 2011;Rice-McDonald 2005;Wainwright 2009)
with an additional 419 participants, but overall study findings and
conclusions are consistent with those of our prior review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence does not support increasing the dose of ICS as part of
a self initiated action plan to treat exacerbations in adults or chil-
dren with mild to moderate asthma. Increased ICS dose is not
associated with a statistically significant reduction in the odds of
requiring rescue oral corticosteroids for the exacerbation, or of
having adverse events, compared with maintenance of a stable ICS
dose. Wide confidence intervals for several outcomes mean that
we cannot rule out possible benefits of this approach.
Implications for research
Additional RCTs comparing increased versus stable ICS doses at
the onset of an exacerbation in specific subgroups (children, ado-
lescents, smokers) are needed, along with RCTs comparing various
ICS doses in head-to-head comparisons by a parallel design. Ran-
domised controlled trials should report detailed subgroup analyses
on variables that may affect response to therapy, such as triggers
for exacerbation, maintenance ICS doses and achieved ICS doses
following step-up therapy.
Future studies should investigate a step-up in ICS dose in ex-
cess of doubling or above a certain ICS threshold dose because
the high-quality studies identified in this review failed to show
clinical benefit with dose doubling. A strategy similar to that of
Oborne 2009, with quadrupling of baseline ICS dose during step-
up therapy to an achieved ICS dose in the range of 2000 mcg/d or
higher in chlorofluorocarbon-propelled beclomethasone dipropi-
onate (CFC-BDP) equivalents, might provemore effective, as pre-
viously suggested, among steroid-naive pre-school-aged children
given 1500 mcg/d (Ducharme 2009).
Future studies should provide documentation on important out-
comes such as the need for rescue oral corticosteroids, unsched-
uled medical resource use and duration of exacerbation as defined
by return of symptoms, lung function and rescue medication use.
These studies should also prospectively document the numbers of
participants experiencing serious and non-serious adverse events,
objectively document compliance with the treatment regimen us-
ing dose counters and clarify the cost-effectiveness of such a strat-
egy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fitzgerald 2004
Methods This 6-month, multi-centre, randomised, double-blind, placebo-controlled, parallel-
group study compared a continued maintenance dose of inhaled corticosteroid vs a dose
doubled at the time of an asthma exacerbation
Conducted at 4 teaching units in Canada
Participants Population
290 participants were randomised; 98 participants experienced an exacerbation and
contributed to the analysis
Participants were 13 years or older. Mean age was 32 years. 28% were male. 14% were
ex-smokers of fewer than 10 pack-years, and 86% were non-smokers
Baseline asthma severity
Mean dose of budesonide: 635 mcg
Mean FEV1: 2.8 L
Mean PEFR: 423 L/min
At least 1 previous asthma exacerbation with mean duration from recent exacerbation
to visit 1 of 131 days
Stable dose of ICS (< 1200 mcg/d of beclomethasone or equivalent twice daily) for 1
month before visit 1
Inclusion criteria
Age ≥ 13; documentation of the diagnosis of asthma within the previous year based on
FEV1 reversibility post bronchodilator, methacholine provoking a fall in FEV1 and/or
diurnal PEF variability
Exclusion criteria
Severe or near fatal asthma; current smokers and ex-smokers > 10 pack-years; baseline
use of LABA; pregnant or lactating women; women of child-bearing potential not on
effective birth control; exacerbation due to chronic sinusitis; hospitalisation in previous
3 months; respiratory tract infection ≤ 1 month before visit 1
Interventions Run-in period
Three- to six-week period whereby participants using other forms of inhalers were
switched to budesonide turbuhaler at an equivalent dose and placed on a twice-daily
dose regimen
Study period
Control arm: maintenance inhaler of budesonide (100, 200 or 400 mcg BID) + placebo
inhaler BID for exacerbations
Study arm: maintenance inhaler of budesonide + inhaler with budesonide to double dose
of ICS (200, 400 or 800 mcg BID) for exacerbations
Other medications allowed
Terbutaline sulphate inhaler as rescue medication; theophylline; anticholinergics; nasal
corticosteroids
Outcomes Primary outcome
The proportion of participants with treatment failure as judged by the need for treatment
with oralmethylprednisolone or anunscheduled visit to a physician ormedical emergency
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Fitzgerald 2004 (Continued)
department due to asthma or unstable asthma after 14 days of treatment
Secondary outcomes
None
Notes Funding source: AstraZeneca Canada Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised to treatment
groups at visit 2 according to a blocked
computer generated randomisation list for
each centre”
Allocation concealment (selection bias) Low risk Central randomisation - assumed that this
meant randomisation was separate from
those dealing with participant details
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind trial” - “The maintenance
dose (MD) group received a maintenance
inhaler of budesonide dispensing 100, 200,
or 400 mg/dose (depending on their main-
tenance therapy) plus an additional inhaler
containing placebo for twice daily use. The
double dose (DD) group received the same
maintenance inhaler as the first group, but
the additional inhaler dispensed 100, 200,
or 400 mg/dose of budesonide as well”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Statistical analysis used the ”all patients
treated“ (APT) approach. Since patients
were ”treated“ only if they had an exacer-
bation, all patients who had at least one
asthma exacerbation after randomisation
and were treated with at least one dose of
additional study drug are included” -Of the
148 randomised to the control group, 115
completed the study (22% dropout), and
117/142 in the intervention group com-
pleted the study (17.6%dropout). Thiswas
considered relatively low and balanced
Selective reporting (reporting bias) Low risk The primary outcome and outcomes of in-
terest to this review were well reported.
Some secondary outcomes not relevant to
our review were presented only graphi-
cally. Peak expiratory flow rate data not
reported for unforeseen technical reasons.
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Fitzgerald 2004 (Continued)
These data were not required as a pre-de-
fined primary or secondary outcome
Foresi 2000
Methods This multi-centre, randomised, double-blind, parallel-group study was designed to com-
pare effects of 6-month treatment with low vs standard dose budesonide in controlling
symptoms and lung function in a group of asthmatic patients with moderate asthma
previously treated with inhaled beclomethasone
Conducted at 14 outpatient clinics in Italy
Moreover, a comparison was made between a continued lowmaintenance dose of budes-
onide vs a short-term increase in daily dose at the time of an asthma exacerbation
Participants Population
213 participants were randomised to 3 treatment groups, and 47 participants experienced
an exacerbation. Groups 2 and 3 accounted for 36 exacerbations and contributed to the
analysis
Participants were 18 to 65 years of age. Mean age was 39 years. 47% were male. 70%
were non-smokers, 22% ex-smokers and 8% smokers
Baseline asthma severity
Moderate asthma
Duration of asthma: 28% < 5 years, 22% 5 to 10 years, 50% > 10 years
Mean FEV1: 74% predicted
Mean PEFR: 75% predicted
41% taking salmeterol, 17% theophylline
Inclusion criteria
Age 18 to 65 years; baseline FEV1 ≥ 50% and ≤ 90% of predicted values; daily PEF
variability ≥ 20% on at least 4 different days during a 2-week period; daily requirement
of inhaled β2 agonist; presence of wheeze, cough, chest tightness, shortness of breath
that interfered with normal daily activity during a 2-week pre-study observation period
Exclusion criteria
Treatment with a high dose of beclomethasone (> 1000 mcg/d); history of seasonal
asthma
Interventions Run-in period
Four-week pre-study treatment period whereby participants were asked to inhale budes-
onide 800 mcg twice daily
Study period
Control arm (Group 3): maintenance inhaler of budesonide 100 mcg BID + placebo
inhaler QID for exacerbations
Study arm (Group 2): maintenance inhaler of budesonide 100 mcg BID + budesonide
200 mcg QID for exacerbations
Other medications allowed
Inhaled β2 agonist; LABA; theophylline; anticholinergics
Outcomes Primary outcome: not specified
Secondary outcomes
• Number of days during which participants experienced cough, wheeze and
shortness of breath
29Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Foresi 2000 (Continued)
• Total number of exacerbations and number of days with exacerbation during the
6-month treatment period
• Number of days during which participants had a PEF value < 70% of baseline or
during which they were taking oral corticosteroids was expressed as a percentage of all
treatment days
• Number of participants with at least 1 exacerbation during the treatment period
• Adverse events
Notes Funding source: Astra Farmaceutici
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Seven patients were withdrawn during the
run-in phase and four patients just af-
ter randomization. Thus, the intention-to-
treat analysis was based on 209 patients.
” “A group of 22 patients discontinued
their treatment: 10 patients were lost at fol-
low-up, 4 patients for adverse events and 8
patients for other reasons. Therefore, out
of 213 randomised patients, a group of
191 patients completed the study.” “Proto-
col violations were detected in 38 patients.
Thus the per-protocol analysis was per-
formed on 175 patients: 56 patients were
included in group 1, 55 patients in group
2, and 64 in group 3.” Dropout was not
given per group but the overall dropout was
low (10.6%) and the ITT group included
98% of those randomised
Selective reporting (reporting bias) Unclear risk The study did not report many of the out-
comes of interest for this review but there
was no evidence to suggest selective report-
ing based on the list of outcomes given
in the paper, although no trial registration
could be found to check what was stated in
advance
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Garrett 1998
Methods This single-centre, randomised, double-blind, placebo-controlled, cross-over trial inves-
tigated the efficacy of an increased dose of inhaled corticosteroid used within the context
of an asthma self management plan for treating exacerbations of asthma
Participants Population
Participants were recruited from a paediatric outpatient department, a department of
respiratory medicine and a local general practice
28 participants were randomised and 18 pairs of exacerbations were available for analysis
The analysis sample revealed participants 6 to 14 years old with a mean age of 8.2 years.
67% were male
Baseline asthma severity
Mild to moderate severity
Mean FEV1: 99% predicted
Mean PEFR: 100% predicted
Inclusion criteria
Age 6 to 14 years; currently taking inhaled corticosteroid prophylaxis (not exceeding
800 mcg/d)
Exclusion criteria
Taking oral corticosteroids, sodiumcromoglycate or LABA; any previous ICUadmission,
recent inpatient care for asthma or any change in dose of inhaled corticosteroids in the
past 2 months; any concurrent illness
Interventions Run-in period
Two-week run-in period during which participants were required to use beclomethasone
via MDI and spacer and a salbutamol MDI. Participants previously taking budesonide
were switched to beclomethasone, but the child’s daily dose was not changed
Study period
Sequence 1: maintenance beclomethasone inhaler (< 800 mcg/d) + placebo inhaler for
exacerbation 1, followed by maintenance beclomethasone inhaler + inhaler with be-
clomethasone to double dose of ICS for exacerbation 2
Sequence 2: maintenance beclomethasone inhaler + inhaler with beclomethasone to
double dose of ICS for exacerbation 1. Maintenance beclomethasone inhaler (< 800
mcg/d) + placebo inhaler for exacerbation 2
Other medications allowed
Salbutamol MDI
Outcomes Primary outcome: not specified
Secondary outcomes
• Morning and evening PEFR
• Diurnal PEFR variability
• Morning and evening symptom scores of cough and wheeze
• Activity symptom score
• Spirometric function including FEV1, FVC and FEF25−75
• Opinion score on effectiveness of the study inhaler as judged by parents
• Adverse events such as hospitalisation or oral corticosteroid requirement
Notes Funding source: New Zealand Asthma Society
Risk of bias
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Garrett 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”After stratification for age and sex, the
children were randomised by the hospital
pharmacist to one of twopossible treatment
sequences for serial exacerbations, placebo
then steroid, or steroid then placebo.“
Allocation concealment (selection bias) Low risk ”By the hospital pharmacist” implies allo-
cation was not done by those conducting
the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind, placebo-controlled”. “The
investigators were blinded to this alloca-
tion.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No mention of any children dropping out
of the trial. “Each child acted as their own
control in a crossover design, and only chil-
dren who had exacerbations in both treat-
ment phases were included in the main
analyses.”
Selective reporting (reporting bias) Low risk The study reported the outcomes stated in
the methods but there was no trial regis-
tration to check that they were consistent.
There was no clear evidence of selective re-
porting
Harrison 2004
Methods This single-centre, randomised, placebo-controlled, parallel-group study investigated
whether doubling the dose of inhaled corticosteroid when asthma control starts to de-
teriorate reduces the number of patients needing prednisolone, and sought to establish
effects on the severity and duration of the subsequent exacerbation
Participants Population
Participants were recruited from local general practices and the asthma research register
390 participants were randomised; 207 experienced an exacerbation and contributed to
the analysis
Participants were 16 years or older. Mean age was 49 years. 33% were male. 3% were
smokers, 36% ex-smokers and 61% never-smokers
Baseline asthma severity
Mean ICS dose: 710 mcg
Mean FEV1: 2.4 L or 80% predicted
Mean PEFR: 384 L/min
Mean symptom score (range 0 to 7): 0.5
35% on LABA
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Harrison 2004 (Continued)
55% required oral corticosteroids, 42% doubled inhaled corticosteroids and 2% did
both in the previous 12 months to treat or prevent asthma exacerbation
Inclusion criteria
Age ≥ 16 years; clinical diagnosis of asthma; taking an inhaled corticosteroid (100 to
2000 mcg/d) on a regular basis; previous course of oral corticosteroids or doubled dose
of inhaled corticosteroid in the previous 12 months for treatment or prevention of an
asthma exacerbation
Exclusion criteria
History of smoking > 10 pack-years; unstable asthma during a 2-week run-in period
Interventions Run-in period
Two-week period whereby participants continued their usual dose of inhaled corticos-
teroid and recorded morning peak flow and daytime symptom scores to ensure asthma
stability
Study period
Control arm: maintenance inhaled corticosteroid (100 to 2000 mcg/d) + identical
placebo inhaler for exacerbations
Study arm: maintenance inhaled corticosteroid (100 to 2000 mcg/d) + identical inhaler
with corticosteroid to double dose of ICS for exacerbations
Participants were to use study inhaler for 14 days in addition to usual treatment when
peak flow or symptoms deteriorated
Other medications allowed
Not specified
Outcomes Primary outcome
Proportion of individuals who needed prednisolone in each group
Secondary outcomes
• Maximum fall in peak flow
• Maximum increase in symptom scores
• Time to recovery of peak flow and symptom scores
Notes Funding source: NHS Executive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent pharmacist randomly al-
located individuals to active or placebo in-
halers using computer-generated random
number tables”
Allocation concealment (selection bias) Low risk “independent pharmacist” implies alloca-
tion was not done by those conducting the
study
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Study report does not explicitly state
”double-blind“, but a placebo was used
which implies that it was not open label,
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Harrison 2004 (Continued)
and text mentions ”A range of active and
placebo study inhalers was available to en-
able the type of inhaler and daily dose to be
matched to patients’ regular inhaled corti-
costeroid, type of inhaler, and dose“”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 8.9% and 10.1% withdrew from inter-
vention and placebo groups, respectively,
which is relatively low and balanced. How-
ever, statistical analyses state, “Our analysis
was by intention-to-treat and per protocol
(i.e. patients who used their study inhaler
as instructed before starting prednisolone)
”, leaving it unclear which was the primary
and how missing data were imputed
Selective reporting (reporting bias) Low risk The study reported outcomes stated in the
methods; several were required by our re-
view. However, again no trial registration
was available to confirm that outcome re-
portingwas consistent with what was stated
in the protocol.We found no clear evidence
of selective reporting
Martinez 2011
Methods This 44-week, randomised, double-blind, placebo-controlled, 4-treatment trial used a
2-by-2 factorial design (2 arms were not relevant to the review and were not included)
The study was conducted at 5 clinical centres in the USA
Participants Population
Participants were recruited from 5 clinical centres
288 were randomised to 1 of 4 groups, of which 143 contributed to this analysis (71
combined group, 72 daily group)
Aged between 5 and 18 years. Mean age was 11.2. 56.6% were male
Baseline asthma severity
Mean dose of budesonide: NR (≤ 160 µg daily equivalent)
Mean FEV1 (pre-BD): 101.5 (11.7) active, 100.1 (10.8) control
Mean PEFR: 321.0 (113.1) active, 301.8 (125.9) control
Approx 5% were taking long-acting beta-agonists. In the previous year, 82% had taken
ICS, 10% had taken a leukotriene inhibitor, 1% had taken salmeterol and none had
taken theophylline or sodium cromoglycate. Participants were required to have had 1 or
2 exacerbations in the previous year
Inclusion criteria
Children and adolescents 6 to 18 years of age, history of mild persistent asthma during
the previous 2 years, qualified for interruption or discontinuation of controller treatment
because their illness was well controlled (as defined in US National Asthma Education
and Prevention Program asthma care guidelines), naive to controller treatment with a
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history of 1 to 2 exacerbations in the previous year, those treated for the previous 8
weeks with monotherapy other than inhaled corticosteroids, and those whose illness was
controlled for the previous 8 weeks on low-dose corticosteroids as monotherapy (≤ 160
mcg daily with a beclomethasone equivalent)
Exclusion criteria
Pre-bronchodilator FEV1 < 60% predicted at the first visit; admitted to hospital for
asthma in the previous year; any asthma exacerbation in the previous 3 months or more
than 2 in the previous year; history of life-threatening asthma exacerbations that required
intubation or mechanical ventilation, or that resulted in a hypoxic seizure
Interventions Run-in period
Four-week run-in period, during which participants received twice-daily treatment with
1 puff of beclomethasone dipropionate and rescue treatment with a placebo inhaler
added to rescue albuterol every time they needed albuterol
Study period
Control arm:maintenance inhaler of beclomethasone 40mcgBID+placeboBID inhaler
and albuterol as rescue for exacerbations
Study arm: maintenance inhaler of beclomethasone 40 mcg BID + 40 mg beclometha-
sone BID and albuterol as rescue for exacerbations (combined group)
Other medications allowed
Low-dose ICS or othermonotherapy inprevious 8weeks. ICS >160mcgbeclomethasone
equivalent not allowed (daily beclomethasone group)
Definition of exacerbation:use ofmore than12 puffs of albuterol in 24 hours (excluding
preventive use before exercise), peak expiratory flow < 70% of consecutive days, peak
expiratory flow < 50% of reference value despite relief treatment, emergency room visit
due to worsening of asthma symptoms
Outcomes Primary outcome
Time to first exacerbation that required treatment with prednisone
Secondary outcomes
Spirometry FEV1, fractional exhaled nitric oxide (FENO), symptom diaries and control
and quality of life questionnaires, linear growth
Notes Funding source: grants from the National Heart, Lung and Blood Institute; TEVA
Pharmaceutical Industries Ltd provided beclomethasone dipropionate-HFA and placebo
Study identifiers: TREXA, NCT00394329
The study used a factorial design, which had implications for the independence of
treatments and subsequent analysis of results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomisation se-
quence, stratified by clinical centre and age
group, was used to randomly assign par-
ticipants to one of four treatment groups”
- “The Data Coordinating Center (DCC;
PennStateHersheyCollege, PA,USA) gen-
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erated the random allocation sequence”
Allocation concealment (selection bias) Low risk “TheDCChad no interactionwith partici-
pants, but was responsible for management
of data and statistical analyses” - “A phar-
maceutical vendor was selected to pack-
age, code, and ship the drug packets to
each clinical centre. When a clinical centre
deemed that a participant was eligible for
randomisation, the clinical centre coordi-
nator logged onto the secure CARE Net-
workwebsite, entered the relevant informa-
tion to confirm participant eligibility, and
received the appropriate drug packet code
to be assigned to the participant”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind, placebo-controlled trial” -
“Drug groups were labelled as A, B, C, and
D to mask statisticians to treatment group
during the first complete run-through of
data analyses”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals from the study were relatively
low and even between the 2 groups in-
cluded in this review: 11.3% in the inter-
vention group (double ICS) and 12.5% in
the control group (stable ICS)
Selective reporting (reporting bias) Low risk The study was prospectively registered
(NCT00394329) and results were well re-
ported in accordance with the protocol
Oborne 2009
Methods This randomised, double-blind, placebo-controlled, parallel-group study investigated
whether a 4-fold increase in the dose of inhaled corticosteroids, started when asthma
control deteriorates, can prevent the need for oral corticosteroids
Participants Population
403 participants were randomised and 94 participants experienced an exacerbation, for
a total of 121 exacerbations contributed to the analysis
Participants 16 years of age or older. Mean age was 56 years. 32% of participants were
male. 10% were smokers, 21% ex-smokers and 69% never-smokers
Baseline asthma severity
Mean ICS dose: 520 mcg
Mean FEV1: 2.2 L or 82% predicted
Mean PEFR: 380 L/min
Inclusion criteria: age > 16 years, stable asthma, treated with ICS (200 to 1000 mcg
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budesonide or equivalent), taken a course of oral corticosteroid or doubled dose of ICS
in the previous 12 months but not in the preceding 4 weeks
Exclusion criteria: > 20 pack-year smoking history, other clinically significant medical
conditions, pregnant or lactating
Interventions Run-inperiod:2-week periodwhereby participants continued their usual dose of inhaled
corticosteroid and recorded morning peak flow and daytime symptom scores to ensure
asthma stability
Study period
Control arm: maintenance inhaled corticosteroid (200 to 1000 mcg/d) + identical
placebo inhaler for exacerbations
Study arm: maintenance inhaled corticosteroid (200 to 1000 mcg/d) + identical inhaler
with corticosteroid to quadruple dose of ICS for exacerbations
Participants were to use study inhaler for 14 days in addition to usual treatment when
peak flow or symptoms deteriorated
Other medications allowed
Not specified
Outcomes Primary outcome
Number of partcipants who had exacerbations of asthma treated with oral corticosteroids
(ITT analysis)
Secondary outcomes
Number of participants who started the study inhaler and went on to require treatment
with oral corticosteroids (per-protocol or modified ITT analysis)
Notes Funding source: Asthma UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An allocation sequence of random per-
muted blocks of 10 was generated using a
random number table by an independent
pharmacist and implemented by one of the
study investigators once participants were
enrolled into the trial”
Allocation concealment (selection bias) Low risk Independent pharma-
cist randomly allocated individuals; “The
authors thank…Sarah Pacey for providing
the randomization schedule and concealed
allocation of masked inhalers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind, placebo-controlled trial” -
“Drug groups were labelled as A, B, C, and
D to mask statisticians to treatment group
during the first complete run-through of
data analyses” - “Active and placebo in-
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Oborne 2009 (Continued)
halers were…identical apart from the pres-
ence or absence of inhaled corticosteroid, to
achieve allocation concealment and blind-
ing of investigators and participants”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Thirty-eight (19.3%) and 39 participants
(18.9%) in the active and placebo groups
withdrew from the study but contributed
data for the intention-to-treat analysis up
to the point at which they left the study. All
participants received their allocated inter-
vention, although 3 were lost to follow-up
with no outcome data (all in the placebo
group), leaving 197 and 203 participants
in the groups receiving active and placebo
inhalers, respectively, for the intention-to-
treat analysis
Selective reporting (reporting bias) Low risk Outcomes reported match those stated in
the prospectively registered protocol and
are relevant to the review
Rice-McDonald 2005
Methods This single-centre, randomised, double-blind, placebo-controlled, cross-over study was
conducted in Australia. The duration of each phase was unclear
Participants Population
22 participants were randomised; 18 experienced an exacerbation in both phases and
contributed to the analysis
Participant mean age 46.5. 40.9% were male
Baseline asthma severity
Mean dose of budesonide: not reported
Mean FEV1: 73% predicted
Mean PEFR: not reported
Inclusion criteria: consenting adults ≥ 18 years of age; physician diagnosed asthma;
reversible airways obstruction evidenced by (i) ≥ 15% reversibility in FEV1 or (ii) ≥
20% variability in PEF over the 2- to 4-week run-in period (% variability defined as
highest PEF-lowest PEF/highest PEF 3100); assessment by investigator that ongoing
treatment with ICS was appropriate; participant did not meet any exclusion criteria
Exclusion criteria: mild asthma when exacerbations with PEF < 80% of best were
thought to be unlikely during the course of the study; demonstration by potential vol-
unteers of erroneous or falsified PEF entries during a 2- to 4-week reliability check; reli-
ability was determined by comparison of self recorded PEF with actual PEF as recorded
on personal Vitalograph 2110 Electronic PEF/FEV1Diaries (Vitalograph, Buckingham,
UK); participants were unaware that the Diaries recorded all PEF values; asthma re-
quiring continuous oral steroids or immunosuppressive-type therapies; concomitant use
of long-acting beta agonists, theophylline or leukotriene receptor antagonists did not
exclude participants from participation
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Interventions Run-in period:
Two- to 4-week run-in period to ensure inclusion criteria, demonstrate competence in
taking ICS via spacer and ensure that asthma was stable
Study period
Control phase: maintenance ICS inhaler (usual type/dose) + same number of placebo
inhalations for 14 days during exacerbations
Study phase: maintenance ICS inhaler (usual type/dose) + same number of ICS inhala-
tions for 14 days during exacerbations
Participants also received placebo oral steroids for 7 days during these phases and their
usual SABA inhaler
Other medications allowed: concomitant use of long-acting beta agonists, theophylline
or leukotriene receptor antagonists was not exclusionary
Outcomes Treatment failure rates; PEF at endpoint; adverse events. The endpoint was assessed at
7 days if no treatment failure, or at time of treatment failure in the event of failure
Outcomes were not defined as primary and secondary
Notes Funding source: Asthma Foundation of Queensland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Low risk “order and allocation of treatment by con-
cealed randomisation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind, double dummy” design -
placebos were used to blind each of the
study medications. “Participants were then
given the first of three treatment packs in a
concealed randomised order”
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 35 randomised participants, 13 subse-
quently withdrew before any asthma exac-
erbations because of: (i) personal choice (6)
; (ii) inadequate compliance (5); (iii) devel-
opment of disease unrelated to asthma (1);
and (iv) relocationprecluding continuation
in the study (1). Baseline characteristics of
the 22 participants contributing data and
described subsequently are found in Table
1
Selective reporting (reporting bias) Low risk The study reported outcomes stated in the
methods; several were those required by our
review. However, again no trial registration
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Rice-McDonald 2005 (Continued)
was available to confirm that outcome re-
portingwas consistent with what was stated
in the protocol.We found no clear evidence
of selective reporting
Wainwright 2009
Methods This 12-month, randomised, double-blind, placebo-controlled, parallel study compared
continued maintenance dose of inhaled corticosteroid vs doubled dose at the time of
childhood asthma exacerbations. It was conducted at 8 centres in south east Queensland
Participants Population
251 children were randomised; 187 participants experienced an exacerbation and con-
tributed to the analysis
38% of children were 3 to 5 years of age, 43% between 6 and 11 and 19% between 12
and 14 years. 60% were male
Baseline asthma severity
Mean dose of ICS: minimum 125 mcg fluticasone/d
Mean FEV1: not reported
Mean PEFR: not reported
(other severity metrics, e.g. baseline ICS requirement or exacerbation frequency)
Inclusion criteria: informed consent obtained from parent/carer and assent from child
when possible. age between 3 and 14 years, doctor diagnosis of asthma and taking regular
ICS (minimum 125 mcg fluticasone/d), at least 1 exacerbation in previous 12 months
requiring admission to hospital, presentation to emergency department + use of oral
steroids
Exclusion criteria: children with co-morbidities that may affect growth; children with
other respiratory illness; unable to obtain informed consent; unable to speak English
Interventions Run-in period: 3-month run-in period including 2 weeks of peak flow measurement
Study period
Control arm: maintenance fluticasone inhaler at child’s usual dose + placebo inhaler to
keep dose stable during exacerbations
Study arm: maintenance fluticasone inhaler at child’s usual dose + study puffer to double
dose during exacerbations. Continued until back to baseline
Other medications allowed: not reported
Outcomes Primary outcome: use of oral steroid rescue and admission to hospital
Secondary outcomes: growth over 12 months; time off work for parents, school for
children; time for peak flow to return to baseline
Notes Funding source: Asthma Foundation Queensland; RCH Foundation Brisbane; flutica-
sone propionate, placebo and peak flow meters provided by GlaxoSmithKline
Study identifier: ACTRN12605000631606
Risk of bias
Bias Authors’ judgement Support for judgement
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Wainwright 2009 (Continued)
Random sequence generation (selection
bias)
Low risk “Stratified block randomisation by age (3-
5, 6-10, 11-14), gender, centre” - “Sequen-
tial study number allocated from a list ac-
cording to blocking details”
Allocation concealment (selection bias) Low risk “...blocking details emailed to Dept of
Epidemiology and Preventative Medicine,
MonashMed School,Melbourne” - “Study
puffer number was allocated. Pre-num-
bered puffers were held at RCH Brisbane
pharmacy”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo inhalers were used to presume this
was to blind participants and personnel
from the study medication, but not explic-
itly described as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 11 in the intervention group (8.7%) and
10 in the control group (8.1%) withdrew
from the study - low and balanced. Only
those having an exacerbationwere included
in themain analyses.No information about
whether an ITT analysis was undertaken
and, if so, how missing data were imputed
Selective reporting (reporting bias) Low risk The study has not been fully published
yet, but it was prospectively registered and
study authors were able to provide us with
data for the outcomes of interest
BID = twice a day.
d = day.
FEF = forced expiratory flow.
FENO = fractional exhaled nitric oxide.
FEV1 = forced expiratory volume in one second.
FVC = forced vital capacity.
HFA =
ICS = inhaled corticosteroids.
ICU = intensive care unit.
ITT = intention-to-treat.
LABA = long-acting beta agonist.
LTRA = leukotriene receptor antagonist.
MDI = metered dose inhaler.
PEF = peak expiratory flow.
PEFR = peak expiratory flow rate.
QID = four times a day.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bateman 2008 Comparison of 2 doses of ciclesonide; not placebo-controlled; uncontrolled asthma at baseline
Boushey 2005 Budesonide vs LTRA for mild persistent asthma
Brand 2011 ICS stopped during run-in; therefore no baseline ICS
Bullard 1996 Systemic corticosteroids vs placebo for COPD, not asthma exacerbations
Clearie 2010 Stopped ICS for 2 weeks before trial. Not focused on exacerbations
Condemi 1999 Low- vs high-dose ICS; not placebo-controlled; uncontrolled asthma at baseline
Connett 1993 No use of ICS at baseline
Currie 2003 Salmeterol-fluticasone vs fluticasone for uncontrolled asthma (not exacerbations)
De Benedictis 2005 Nebulised fluticasone vs budesonide; not placebo-controlled; no use of ICS at baseline
Devidayal 1999 Nebulised budesonide vs oral prednisone; not placebo-controlled; no use of ICS at baseline
Fitzgerald 2000 Use of systemic corticosteroids first; not placebo-controlled
Greening 1994 BDP + salmeterol vs high-dose BDP; not placebo-controlled; uncontrolled asthma at baseline
GSK 2005 Not placebo-controlled; uncontrolled asthma at baseline
Hedlin 1999 Inhaled budesonide vs oral betamethasone; not placebo-controlled
Heinig 1999 Budesonide vs fluticasone; not placebo-controlled; uncontrolled asthma at baseline
Karpel 2007 Severe persistent asthma (not exacerbations); participants on oral corticosteroids at baseline
La Rosa 1997 Salbutamol-flunisolide vs salbutamol; not placebo-controlled
Lee-Wong 2002 Inhaled flunisolide vs systemic corticosteroids following IV corticosteroids; not placebo-controlled
Lemanske 2010 Three step-up options and no stable arm. ICS increased but not in response to exacerbation
Leuppi 2002 Unstable dose of ICS (dose reduction) before exacerbation
Levy 1996 Fluticasone vs oral prednisolone; not placebo-controlled; not all participants on ICS at baseline
Manjra 2000 Nebulised fluticasone vs oral prednisolone; not placebo-controlled; not all participants on ICS at baseline
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Matz 2001 Salmeterol-fluticasone vs high-dose fluticasone for stable asthma (not exacerbations)
Milani 2004 No use of ICS at baseline
Nana 1998 Inhaled budesonide vs oral prednisolone; not placebo-controlled
Nuhoglu 2001 No use of ICS at baseline
O’Connor 2010 ICS given but not in response to exacerbation
Pedersen 2009 ICS given but not in response to exacerbation
Razi 2008 Two dosing regimens of nebulised budesonide; not placebo-controlled
Rodrigo 1998 No use of ICS at baseline
Rodrigo 2005 Inhaled fluticasone vs IV hydrocortisone; no use of ICS at baseline
Schuh 2000 Inhaled fluticasone vs oral prednisolone; not all participants on ICS at baseline
Schuh 2006 Inhaled fluticasone vs oral prednisolone; not all participants on ICS at baseline
Sekerel 2005 Not all participants on ICS at baseline
Singhi 1999 Not all participants on ICS at baseline
Svedmyr 1995 ICS started at onset of URTI but not a confirmed asthma exacerbation; no ICS use at baseline
Volovitz 1998 Inhaled budesonide vs oral prednisone; not placebo-controlled; no ICS use at baseline
Wilson 1990 Not all participants on ICS at baseline
Yousef 2012 No stable ICS arm
BDP = beclomethasone dipropionate.
COPD = chronic obstructive pulmonary disease.
ICS = inhaled corticosteroids.
IV = intravenous.
LTRA = leukotriene receptor agonists.
URTI = upper respiratory tract infection.
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Characteristics of ongoing studies [ordered by study ID]
NCT02066129
Trial name or title Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants This is a double-blind, parallel-group trial, including a total of 250 participants, 5 to 11 years of age, with
a diagnosis of asthma and a history of at least 1 asthma exacerbation treated with oral corticosteroids in the
prior year
Interventions All participants will be treated for 48 weeks with open-label fluticasone 44 mcg 2 puffs twice daily. During
the 48-week treatment period, participants will receive randomised blinded therapy for 7 days each time they
enter the “yellow zone” (at the onset of symptoms previously associated with upper respiratory illnesses and
subsequent asthma exacerbations). Yellow zone therapy will be fluticasone 44 or 220 mcg 2 puffs twice daily
Outcomes The primary outcome is listed as the rate of severe asthma exacerbations treated with oral corticosteroids
during the 48-week treatment period
Starting date July 2014
Contact information David Mauger, PhD (dtm5@psu.edu)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Increased versus stable doses of ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure - need for
systemic corticosteroids
(primary outcome, all
randomised participants)
7 1520 Odds Ratio (Fixed, 95% CI) 0.89 [0.68, 1.18]
2 Treatment failure - need for
systemic corticosteroids (of
those starting inhaler)
7 766 Odds Ratio (Random, 95% CI) 0.84 [0.54, 1.30]
3 Unscheduled physician visits 3 931 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.41]
4 Unscheduled acute care, ED visit
or hospital admission
3 450 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.24, 3.98]
5 Duration of exacerbation 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 days to symptom recovery 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 days to lung function
recovery
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Serious and non-serious adverse
events
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Serious adverse events 2 394 Odds Ratio (M-H, Fixed, 95% CI) 1.69 [0.77, 3.71]
6.2 Non-serious adverse
events
2 142 Odds Ratio (M-H, Fixed, 95% CI) 2.15 [0.68, 6.73]
Comparison 2. Primary outcome subgroup and sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subgrouped by age 7 Odds Ratio (Fixed, 95% CI) 0.89 [0.68, 1.18]
1.1 Children 3 Odds Ratio (Fixed, 95% CI) 0.93 [0.61, 1.41]
1.2 Adults 4 Odds Ratio (Fixed, 95% CI) 0.87 [0.60, 1.26]
2 Subgrouped by time to treatment
initiation
7 Odds Ratio (Fixed, 95% CI) 0.89 [0.68, 1.18]
2.1 < 48 hours 4 Odds Ratio (Fixed, 95% CI) 0.92 [0.66, 1.28]
2.2 ≥ 48 hours 3 Odds Ratio (Fixed, 95% CI) 0.84 [0.51, 1.39]
3 Subgrouped by maintenance
ICS dose
6 Odds Ratio (Fixed, 95% CI) 0.88 [0.67, 1.16]
3.1 Low 1 Odds Ratio (Fixed, 95% CI) 1.17 [0.57, 2.40]
3.2 Medium 3 Odds Ratio (Fixed, 95% CI) 0.78 [0.52, 1.18]
3.3 High 2 Odds Ratio (Fixed, 95% CI) 0.91 [0.58, 1.42]
4 Subgrouped by ICS dose during
exacerbation
6 Odds Ratio (Fixed, 95% CI) 0.88 [0.67, 1.16]
4.1 Low 1 Odds Ratio (Fixed, 95% CI) 1.17 [0.57, 2.40]
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4.2 High 5 Odds Ratio (Fixed, 95% CI) 0.84 [0.62, 1.13]
5 Subgrouped by ICS fold increase 7 Odds Ratio (Fixed, 95% CI) 0.89 [0.68, 1.18]
5.1 Double dose 6 Odds Ratio (Fixed, 95% CI) 0.98 [0.72, 1.34]
5.2 Quadruple dose 1 Odds Ratio (Fixed, 95% CI) 0.60 [0.32, 1.13]
6 Sensitivity analysis:
parallel-group studies only
5 1474 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.66, 1.16]
7 Sensitivity analysis:
independently funded studies
only
5 Odds Ratio (Fixed, 95% CI) 0.84 [0.62, 1.12]
Analysis 1.1. Comparison 1 Increased versus stable doses of ICS, Outcome 1 Treatment failure - need for
systemic corticosteroids (primary outcome, all randomised participants).
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 1 Treatment failure - need for systemic corticosteroids (primary outcome, all randomised participants)
Study or subgroup Increased ICS Stable ICS log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Fitzgerald 2004 142 148 0.3546 (0.4575) 9.6 % 1.43 [ 0.58, 3.49 ]
Garrett 1998 14 14 1.6822 (1.5725) 0.8 % 5.38 [ 0.25, 117.24 ]
Harrison 2004 192 198 -0.0638 (0.3142) 20.3 % 0.94 [ 0.51, 1.74 ]
Martinez 2011 71 72 0.1547 (0.3676) 14.8 % 1.17 [ 0.57, 2.40 ]
Oborne 2009 197 203 -0.5053 (0.3184) 19.8 % 0.60 [ 0.32, 1.13 ]
Rice-McDonald 2005 (1) 9 9 0 (0.5726) 6.1 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 127 124 -0.2471 (0.2651) 28.5 % 0.78 [ 0.46, 1.31 ]
Total (95% CI) 752 768 100.0 % 0.89 [ 0.68, 1.18 ]
Heterogeneity: Chi2 = 4.72, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
analysis which was conducted using generic inverse variance, the participant totals are for display only.
(1) The total number of participants in the crossover studies were halved across groups so as to accurately reflect the total number of people in the analysis. This did not
affect the
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Analysis 1.2. Comparison 1 Increased versus stable doses of ICS, Outcome 2 Treatment failure - need for
systemic corticosteroids (of those starting inhaler).
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 2 Treatment failure - need for systemic corticosteroids (of those starting inhaler)
Study or subgroup Increased ICS Stable ICS log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Fitzgerald 2004 47 52 0.4935 (0.4963) 13.0 % 1.64 [ 0.62, 4.33 ]
Garrett 1998 (1) 9 9 1.7238 (1.5858) 1.9 % 5.61 [ 0.25, 125.45 ]
Harrison 2004 110 97 -0.34 (0.3499) 19.2 % 0.71 [ 0.36, 1.41 ]
Martinez 2011 71 72 0.1547 (0.3676) 18.4 % 1.17 [ 0.57, 2.40 ]
Oborne 2009 56 38 -1.2993 (0.4597) 14.3 % 0.27 [ 0.11, 0.67 ]
Rice-McDonald 2005 9 9 0 (0.5726) 10.8 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 93 94 -0.2377 (0.2936) 22.4 % 0.79 [ 0.44, 1.40 ]
Total (95% CI) 395 371 100.0 % 0.84 [ 0.54, 1.30 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 10.37, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
analysis which was conducted using generic inverse variance, the participant totals are for display only.
(1) The total number of participants in the crossover studies were halved across groups so as to accurately reflect the total number of people in the analysis. This did not
affect the
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Analysis 1.3. Comparison 1 Increased versus stable doses of ICS, Outcome 3 Unscheduled physician visits.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 3 Unscheduled physician visits
Study or subgroup Increased ICS Stable ICS Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fitzgerald 2004 (1) 1/142 0/148 0.9 % 3.15 [ 0.13, 77.93 ]
Harrison 2004 31/192 28/198 43.1 % 1.17 [ 0.67, 2.04 ]
Wainwright 2009 35/127 41/124 56.0 % 0.77 [ 0.45, 1.32 ]
Total (95% CI) 461 470 100.0 % 0.96 [ 0.66, 1.41 ]
Total events: 67 (Increased ICS), 69 (Stable ICS)
Heterogeneity: Chi2 = 1.65, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours increased ICS Favours stable ICS
(1) Denominators are the full randomised population
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Analysis 1.4. Comparison 1 Increased versus stable doses of ICS, Outcome 4 Unscheduled acute care, ED
visit or hospital admission.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 4 Unscheduled acute care, ED visit or hospital admission
Study or subgroup Increased ICS Stable ICS
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Garrett 1998 0/28 0/28 Not estimable
Martinez 2011 0/71 0/72 Not estimable
Wainwright 2009 4/127 4/124 100.0 % 0.98 [ 0.24, 3.98 ]
Total (95% CI) 226 224 100.0 % 0.98 [ 0.24, 3.98 ]
Total events: 4 (Increased ICS), 4 (Stable ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
Analysis 1.5. Comparison 1 Increased versus stable doses of ICS, Outcome 5 Duration of exacerbation.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 5 Duration of exacerbation
Study or subgroup Increased ICS Stable ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 days to symptom recovery
Harrison 2004 (1) 110 6.8 (5.8209) 97 6.1 (6.9464) 0.70 [ -1.06, 2.46 ]
2 days to lung function recovery
Harrison 2004 (2) 110 6.8 (5.8209) 97 7 (6.4502) -0.20 [ -1.88, 1.48 ]
-4 -2 0 2 4
Favours increased ICS Favours stable ICS
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(1) Presumed typo in paper for lower CI. Entered upper CI which calculated lower as 4.7. Only those who started the study inhaler.
(2) Only those who started the study inhaler
Analysis 1.6. Comparison 1 Increased versus stable doses of ICS, Outcome 6 Serious and non-serious
adverse events.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 1 Increased versus stable doses of ICS
Outcome: 6 Serious and non-serious adverse events
Study or subgroup Increased ICS Stable ICS Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Serious adverse events
Martinez 2011 1/71 1/72 10.0 % 1.01 [ 0.06, 16.54 ]
Wainwright 2009 (1) 17/127 10/124 90.0 % 1.76 [ 0.77, 4.02 ]
Subtotal (95% CI) 198 196 100.0 % 1.69 [ 0.77, 3.71 ]
Total events: 18 (Increased ICS), 11 (Stable ICS)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Non-serious adverse events
Foresi 2000 (2) 2/17 2/31 29.4 % 1.93 [ 0.25, 15.12 ]
Oborne 2009 9/56 3/38 70.6 % 2.23 [ 0.56, 8.86 ]
Subtotal (95% CI) 73 69 100.0 % 2.15 [ 0.68, 6.73 ]
Total events: 11 (Increased ICS), 5 (Stable ICS)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
1.79, 95% CI 0.80 to 3.99))
(1) Full randomised population denominators used for both studies. Results are similar and conclusions do not change if numbers for only those who took the study
medication were used (OR
(2) Denominators used are those that took the exacerbation inhalers, not the total numbers randomised.
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Analysis 2.1. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 1 Subgrouped by
age.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 1 Subgrouped by age
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Children
Garrett 1998 1.6822 (1.5725) 0.8 % 5.38 [ 0.25, 117.24 ]
Martinez 2011 0.1547 (0.3676) 14.8 % 1.17 [ 0.57, 2.40 ]
Wainwright 2009 -0.2471 (0.2651) 28.5 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 44.2 % 0.93 [ 0.61, 1.41 ]
Heterogeneity: Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Adults
Fitzgerald 2004 0.3546 (0.4575) 9.6 % 1.43 [ 0.58, 3.49 ]
Harrison 2004 -0.0638 (0.3142) 20.3 % 0.94 [ 0.51, 1.74 ]
Oborne 2009 -0.5053 (0.3184) 19.8 % 0.60 [ 0.32, 1.13 ]
Rice-McDonald 2005 0 (0.5726) 6.1 % 1.00 [ 0.33, 3.07 ]
Subtotal (95% CI) 55.8 % 0.87 [ 0.60, 1.26 ]
Heterogeneity: Chi2 = 2.60, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
Total (95% CI) 100.0 % 0.89 [ 0.68, 1.18 ]
Heterogeneity: Chi2 = 4.72, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
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Analysis 2.2. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 2 Subgrouped by
time to treatment initiation.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 2 Subgrouped by time to treatment initiation
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 < 48 hours
Harrison 2004 -0.0638 (0.3142) 20.3 % 0.94 [ 0.51, 1.74 ]
Martinez 2011 0.1547 (0.3676) 14.8 % 1.17 [ 0.57, 2.40 ]
Rice-McDonald 2005 0 (0.5726) 6.1 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 -0.2471 (0.2651) 28.5 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 69.8 % 0.92 [ 0.66, 1.28 ]
Heterogeneity: Chi2 = 0.83, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2≥ 48 hours
Fitzgerald 2004 0.3546 (0.4575) 9.6 % 1.43 [ 0.58, 3.49 ]
Garrett 1998 1.6822 (1.5725) 0.8 % 5.38 [ 0.25, 117.24 ]
Oborne 2009 -0.5053 (0.3184) 19.8 % 0.60 [ 0.32, 1.13 ]
Subtotal (95% CI) 30.2 % 0.84 [ 0.51, 1.39 ]
Heterogeneity: Chi2 = 3.81, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 100.0 % 0.89 [ 0.68, 1.18 ]
Heterogeneity: Chi2 = 4.72, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
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Analysis 2.3. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 3 Subgrouped by
maintenance ICS dose.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 3 Subgrouped by maintenance ICS dose
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low
Martinez 2011 (1) 0.1547 (0.3676) 15.0 % 1.17 [ 0.57, 2.40 ]
Subtotal (95% CI) 15.0 % 1.17 [ 0.57, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 Medium
Harrison 2004 (2) -0.0638 (0.3142) 20.5 % 0.94 [ 0.51, 1.74 ]
Oborne 2009 (3) -0.5053 (0.3184) 19.9 % 0.60 [ 0.32, 1.13 ]
Rice-McDonald 2005 (4) 0 (0.5726) 6.2 % 1.00 [ 0.33, 3.07 ]
Subtotal (95% CI) 46.6 % 0.78 [ 0.52, 1.18 ]
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
3 High
Fitzgerald 2004 (5) 0.3546 (0.4575) 9.7 % 1.43 [ 0.58, 3.49 ]
Wainwright 2009 (6) -0.2471 (0.2651) 28.8 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 38.4 % 0.91 [ 0.58, 1.42 ]
Heterogeneity: Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 100.0 % 0.88 [ 0.67, 1.16 ]
Heterogeneity: Chi2 = 3.40, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.92, df = 2 (P = 0.63), I2 =0.0%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
(1) Baseline dose was 80 mcg/day beclomethasone, low dose for children
(2) Baseline mean dose 710 mcg/day (presumed BDP, not described otherwise), medium dose for adults
(3) Baseline mean dose 520 mcg/day (presumed BDP, not described otherwise), medium dose for adults
(4) Maintenance dose assumed from median achieved fluticasone doses of 1000-2000 mcg/day
(5) Baseline mean budesonide dose 635 mcg/day, high dose for adults
(6) 51/67 children were on fluticasone 500mcg/day fluticasone which is on the cusp of medium and high dose, and the rest were on > 500 mcg/day
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Analysis 2.4. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 4 Subgrouped by
ICS dose during exacerbation.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 4 Subgrouped by ICS dose during exacerbation
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low
Martinez 2011 (1) 0.1547 (0.3676) 15.0 % 1.17 [ 0.57, 2.40 ]
Subtotal (95% CI) 15.0 % 1.17 [ 0.57, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 High
Fitzgerald 2004 (2) 0.3546 (0.4575) 9.7 % 1.43 [ 0.58, 3.49 ]
Harrison 2004 (3) -0.0638 (0.3142) 20.5 % 0.94 [ 0.51, 1.74 ]
Oborne 2009 (4) -0.5053 (0.3184) 19.9 % 0.60 [ 0.32, 1.13 ]
Rice-McDonald 2005 (5) 0 (0.5726) 6.2 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 (6) -0.2471 (0.2651) 28.8 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 85.0 % 0.84 [ 0.62, 1.13 ]
Heterogeneity: Chi2 = 2.71, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 100.0 % 0.88 [ 0.67, 1.16 ]
Heterogeneity: Chi2 = 3.40, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.41), I2 =0.0%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
(1) The study inhaler doubled the ICS dose to beclomethasone 160 mcg/day, still considered a low dose for children
(2) Based on the already high dose mean at baseline, the double dose was assumed to be around 1200 (also in the high dose category)
(3) Based on the medium baseline dose, we assumed the double dose would be comfortably in the high dose category for adults
(4) Based on the medium baseline dose, we assumed the quadruple dose would be comfortably in the high dose category for adults
(5) The achieved mean doses were reported as 1000 and 2000 mcg of fluticasone per day which are both within the high dose category for adults
(6) Baseline dose was just to be high for children, so the increased dose was also high
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Analysis 2.5. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 5 Subgrouped by
ICS fold increase.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 5 Subgrouped by ICS fold increase
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Double dose
Fitzgerald 2004 0.3546 (0.4575) 9.6 % 1.43 [ 0.58, 3.49 ]
Garrett 1998 1.6822 (1.5725) 0.8 % 5.38 [ 0.25, 117.24 ]
Harrison 2004 -0.0638 (0.3142) 20.3 % 0.94 [ 0.51, 1.74 ]
Martinez 2011 0.1547 (0.3676) 14.8 % 1.17 [ 0.57, 2.40 ]
Rice-McDonald 2005 0 (0.5726) 6.1 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 -0.2471 (0.2651) 28.5 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 80.2 % 0.98 [ 0.72, 1.34 ]
Heterogeneity: Chi2 = 2.82, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Quadruple dose
Oborne 2009 -0.5053 (0.3184) 19.8 % 0.60 [ 0.32, 1.13 ]
Subtotal (95% CI) 19.8 % 0.60 [ 0.32, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 100.0 % 0.89 [ 0.68, 1.18 ]
Heterogeneity: Chi2 = 4.72, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 1.89, df = 1 (P = 0.17), I2 =47%
0.01 0.1 1 10 100
Favours increased ICS Favours stable ICS
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Analysis 2.6. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 6 Sensitivity
analysis: parallel-group studies only.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 6 Sensitivity analysis: parallel-group studies only
Study or subgroup Increased ICS Stable ICS Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fitzgerald 2004 12/142 9/148 8.0 % 1.43 [ 0.58, 3.50 ]
Harrison 2004 22/192 24/198 20.7 % 0.94 [ 0.51, 1.74 ]
Martinez 2011 22/71 20/72 13.6 % 1.17 [ 0.57, 2.40 ]
Oborne 2009 18/197 29/203 25.7 % 0.60 [ 0.32, 1.13 ]
Wainwright 2009 41/127 47/124 31.9 % 0.78 [ 0.46, 1.31 ]
Total (95% CI) 729 745 100.0 % 0.87 [ 0.66, 1.16 ]
Total events: 115 (Increased ICS), 129 (Stable ICS)
Heterogeneity: Chi2 = 3.35, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 2.7. Comparison 2 Primary outcome subgroup and sensitivity analyses, Outcome 7 Sensitivity
analysis: independently funded studies only.
Review: Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Comparison: 2 Primary outcome subgroup and sensitivity analyses
Outcome: 7 Sensitivity analysis: independently funded studies only
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Harrison 2004 -0.0638 (0.3142) 22.7 % 0.94 [ 0.51, 1.74 ]
Martinez 2011 0.1547 (0.3676) 16.6 % 1.17 [ 0.57, 2.40 ]
Oborne 2009 -0.5053 (0.3184) 22.1 % 0.60 [ 0.32, 1.13 ]
Rice-McDonald 2005 0 (0.5726) 6.8 % 1.00 [ 0.33, 3.07 ]
Wainwright 2009 -0.2471 (0.2651) 31.9 % 0.78 [ 0.46, 1.31 ]
Total (95% CI) 100.0 % 0.84 [ 0.62, 1.12 ]
Heterogeneity: Chi2 = 2.17, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Favours increased ICS Favours stable ICS
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study ID N ran-
domised*
N (%)
who took
study in-
haler
Country
(N
centres)
Design Age range Mainte-
nance ICS
Exacer-
bation in-
haler
Funding Asthma
severity
Fitzgerald
2004
290 98 (34) Canada (4) 6-month
parallel,
DB, PC
13+ Budes-
onide 100,
200 or 400
mcg BID
(mean
635 mcg/d
BDP)
Budes-
onide 100,
200 or 400
mcg
to double
dose for 14
days
Control:
placebo
As-
traZeneca
FEV1 2.
8 L, PEFR
423 L/
min, ICS <
1200 mcg/
d
Foresi
2000
142 36 (25) Italy (14) 6-month
parallel,
18-65 Budes-
onide 100
Budes-
onide 200
Astra Far-
maceutici
FEV1
74%,
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Table 1. Summary of study characteristics (Continued)
DB, PC mcg BID mcg QID
to double
usual dose
Control:
placebo
PEFR
75%, 41%
on LABA,
ICS <
1000 mcg/
d
Garrett
1998
28 18 (64) New
Zealand
(1)
6-month
cross-over,
DB, PC
6-14 Be-
clometha-
sone < 800
mcg/d
Matching
be-
clometha-
sone
to double
dose
Control:
placebo
New
Zealand
Asthma
Society
FEV1
99%,
PEFR
100%, ICS
< 800mcg/
d
Harrison
2004
390 207 (53) UK (1) 1-year par-
allel, DB,
PC
16+ Usual ICS
dose
(mean
710 mcg/d
BDP)
Match-
ing ICS in-
haler
to double
dose for 14
days
Control:
placebo
NHS Ex-
ecutive
FEV1 2.4
L/
80%, PEF
384 L/
min, 35%
on LABA,
ICS 100-
2000 mcg/
d
Martinez
2011
143 143 (100) USA (5) 44-
week par-
allel, DB,
PC
6-18 Be-
clometha-
sone 40
mcg BID
Be-
clometha-
sone 40
mcg BID
to double
dose
Control:
placebo
NHLBI 5%
on LABA,
recent ad-
mission or
OCS, max
160 mcg
bec/d
Oborne
2009
403 94 (23) UK (1) 1-year par-
allel, DB,
PC
16+ Usual ICS
dose
(mean
520 mcg/d
BDP)
Match-
ing ICS in-
haler
to double
dose for 14
days
Control:
placebo
Asthma
UK
FEV1 2.2
L/
82%, PEF
380 L/
min, ICS
200-1000
mcg/d, re-
cent OCS
Rice-
McDonald
2005
22 18 (82) Australia
(1)
Cross-over
until exac-
erbation in
each phase
18+ Usual fluti-
ca-
sone dose
(range not
specified)
Match-
ing ICS in-
haler
to double
dose for 14
Asthma
Founda-
tion
of Queens-
land
Excluded
mild
asthma
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Table 1. Summary of study characteristics (Continued)
days
Control:
placebo
Wain-
wright
2009
251 187 (75) Australia
(8)
1-year par-
allel, PC
3-14 Fluti-
casone 125
mcg/
d, or usual
higher
dose
Matching
fluticasone
to double
dose for 14
days
Control:
placebo
Asthma
Founda-
tion
of Queens-
land
Recent
ED, OCS
or admis-
sion; fluti-
casone
at least 125
mcg/d
DB = double-blind, NHLBI = National Heart, Lung and Blood Institute, PC = placebo-controlled, UK = United Kingdom, USA =
United States of America. Asthma severity statistics are mean values for the total population in each study. Percentages are means of
lung function measured as a percentage of participants’ predicted values
* The number randomised to the groups relevant to this review
A P P E N D I C E S
Appendix 1. Search strategy for the previous version of this review
All records in the Specialised Register coded as ‘asthma’ were searched using the following terms:
(exacerbat* OR acute* or status* or severe* OR worsen* OR emergenc* OR attack* or crisis) and (dose* or dosing or dosage) and
(doubl* or increas*) OR “dose response” or “drug dose”) and (glucocorticoid* OR corticosteroid* OR “inhaled steroid*”OR fluticasone
OR Flovent OR beclomethasone OR Becloforte OR budesonide OR Pulmicort OR flunisolide OR Aerobid OR triamcinolone OR
Beclovent OR Azmacort OR Vanceril OR Becotide OR Flixotide OR Aerobec OR Mometasone OR Qvar or ciclesonide or Alvesco)
Appendix 2. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
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(Continued)
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
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14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 3. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All
#6 ICS:TI,AB
#7 (beclomethasone* or beclometasone* OR triamcinolone* OR fluticasone* OR budesonide* OR betamethasone* OR flunisolide*
OR ciclesonide* OR mometasone*)
#8 (inhal*) NEAR5 (steroid* or corticosteroid* or glucocorticoid*)
#9 #5 or #6 or #7 or #8
#10 MeSH DESCRIPTOR Dose-Response Relationship, Drug
#11 (dose* or dosing or dosage) AND (doubl* or increas*)
#12 step-up* OR (step* NEXT up*)
#13 dose* NEXT reponse*
#14 drug* NEXT dose*
#15 #10 or #11 or #12 or #13 or #14
#16 MeSH DESCRIPTOR Disease Progression
#17 exacerbat* OR acute* or status* or severe* OR worsen* OR emergenc* OR attack* or crisis
#18 #16 or #17
#19 #4 AND #9 AND #15 AND #18
[Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, asthma]
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F E E D B A C K
feedback, 27 October 2010
Summary
The abstract and document appear to mix up use of mg and mcg throughout the document. I assume the units should be mcg
throughout but mg is used widely, particularly in the abstract. This could potentially lead to significant error and risk to patient safety.
Could you confirm whether these are errors?
Reply
We are very grateful to the author for highlighting the typo in the review, along with others who pointed this out. We have corrected
the typo and apologise for any confusion caused.
Contributors
Vanessa Chapman
WH A T ’ S N E W
Last assessed as up-to-date: 24 March 2016.
Date Event Description
24 March 2016 New search has been performed Three new studies (Martinez 2011; Rice-McDonald
2005; Wainwright 2009) including 419 additional par-
ticipants were included in this review update
24 March 2016 New citation required but conclusions have not changed Although additional data have been included in this re-
view, the original conclusions remain unchanged
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 10, 2010
Date Event Description
8 November 2010 New citation required but conclusions have not
changed
Feedback has triggered a new citation version
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(Continued)
8 November 2010 Feedback has been incorporated We received feedback and corrected several typos by
which mcg was confused with mg
C O N T R I B U T I O N S O F A U T H O R S
KK: lead for the 2015 update. Sift and study selection, data extraction, analysis, risk of bias and GRADE assessment, write-up.
MQ: review work for the 2015 update. Sift and study selection, data extraction, analysis, risk of bias assessment, write-up.
BQ: protocol development, study assessment, data extraction and write-up of the previous version, critical appraisal of this update.
FD: protocol development; interpretation of data, write-up and editorial sign-off of the previous version, critical review of data
interpretation and write-up of this update.
D E C L A R A T I O N S O F I N T E R E S T
Kayleigh Kew: none.
Michael Quinn: none.
Bradley Quon: none.
Francine Ducharme: grant support for investigator-initiated studies from Merck and Co., unrestricted donations from Merck, Glax-
oSmithKline, and Takeda, to support an electronic database of children consulting for asthma; member of the advisory boards of
Boehringer Ingelheim.
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do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The data synthesis section of our protocol initially read as follows “we will report fixed-effect rate ratios, such as the rate of the need
for rescue systemic corticosteroids per person-years of follow up in treatment and control groups”. We have made two changes to this
statement. We used the fixed-effect model if we found no significant heterogeneity, otherwise we used the random-effects model. As we
could not obtain individual participant level data, we could not calculate event rates; therefore we defaulted to comparing frequency of
events (numbers of participants requiring rescue systemic corticosteroids in treatment and control groups).
We did not discuss in the protocol unit of analysis issues for parallel and cross-over studies. We did not pool parallel and cross-over
studies in previous versions, but we were able to pool them in this update. For dichotomous outcomes, we pooled studies using Mantel-
Haenszel (M-H) odds ratios unless investigators reported a low number of events requiring Peto odds ratios. In the previous version,
we obtained the marginal odds ratio from the cross-over trial by comparing the number of participants who needed increased doses of
oral corticosteroids (but not receiving placebo) with the number needing oral corticosteroids while receiving placebo (but not given
double-dose ICS). In this version, we included cross-over data by obtaining these two-by-two data and applying a formula to account
for inter-correlation of matched pairs (Elbourne 2002).
The previous version of this review included a funnel plot, which we did not include this time, as the protocol stated that this would
be done only if more than 10 trials were included.
For the primary outcome, we changed the denominator from the number of participants requiring study inhaler to the number of
participants randomised, consistent the intention-to-treat analysis. As a secondary outcome, we re-analysed treatment failure on the
basis of the number of participants requiring the study inhaler.
We added magnitude of ICS dose increase (two-fold vs four-fold) as a subgroup analysis. Post hoc subgroup analyses were previously
performed on the modified intention-to-treat analysis of the primary outcome, but this was not repeated for the current update.
For this update, we defined the sensitivity analyses to clarify which studies would be removed from the primary analysis. The meaning
of the study design and the source of study funding did not change, but we chose to remove studies at high risk of selection bias from the
methodological quality sensitivity analysis. We considered this to be an important factor related to bias in these studies, as inadequate
allocation procedures could have resulted in unbalanced groups, which would have had an important effect on the numbers having
exacerbations for each treatment.
We encountered uncertainty about the number of participants included in analyses, especially for dichotomous outcomes. For this
reason, we took the following approach, which we added to the methods: “For dichotomous outcomes, where we did not know whether
the number of events were for the entire population or only those taking the study inhaler, we used the total number randomised per
group as the denominator. We performed sensitivity analyses using the number taking their study inhaler as the denominator to test
this assumption.”
We extended the definition of serious adverse events in the list of outcomes to include prolongation of hospitalisation or disability as
the standard definition. We also noted in the analysis whether definitions used within studies differed.
In Types of participants, we extended the definition of exacerbations to include a set of criteria pre-defined in the included studies,
because guidelines were not always cited, but it was clear that a list of criteria had to be met before the study medication could be
initiated.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage]; Anti-Asthmatic Agents [∗administration & dosage]; Asthma [∗drug therapy];
Beclomethasone [administration & dosage]; Chronic Disease; Disease Progression; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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